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ABSTRACT 
 
BACKGROUND: sudden cardiac death (SCD) due to ventricular fibrillation (VF) is a 
dramatic and usually unexpected event in young patients with cardiomyopathies 
and channelopathies including Brugada syndrome (BS). Implantable cardioverter 
defibrillator (ICD) is the only proven life-saving therapy in these patients, able to 
reduce mortality by interrupting VF.  However, ICD is not free from complications 
and markedly affects quality of life, particularly in young and active subjects. 
Markers of increased arrhythmic risk are strongly needed to identify those patients 
who most benefit from ICD therapy. It has been reported a high incidence of BS in a 
Japanese population with a progressive neuromuscular disorder, the KeŶŶedǇ͛s 
disease (KD). Whether the same prevalence of Brugada ECG is found in the Italian 
patients with KD and it represents a predictor of malignant arrhythmic outcome 
remains to be established. 
AIMS: we aimed to: 1) found predictors of major arrhythmic events in BS, by 
assessing the prognostic value of clinical and electrocardiographic parameters; 2) 
evaluate the risk/benefit ratio of ICD in young patients (ζ35 years old) with 
cardiomyopathies and channelopathies including BS; 3) to determine the prevalence 
of the Brugada ECG pattern in a large Italian cohort of patients with KD. 
METHODS: we performed three different studies. First, we conducted a prospective 
study on 272 patients with a diagnostic (type 1) Brugada ECG either spontaneous or 
drug-induced. The primary end-point of the study was a combined endpoint 
including SCD, cardiac arrest, and appropriate ICD interventions. Second, we 
enrolled 96 consecutive patients with cardiomyopathies and channelopathies who 
were 18–35 years old at the time of ICD implantation. The study end points were 
cardiac mortality, appropriate ICD intervention, inappropriate ICD intervention and 
device-related complication. Third, we analysed 73 ECG tracings of Italian patients 
with KD. 
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RESULTS: the main results for each study were as follows: 1) during a mean follow-
up of 85±44 months, 17 patients (6.3%) experienced η1 major arrhythmic events 
(annual rate 0.9%) such as appropriate ICD intervention (N=13) and SCD (N=4). 
History of syncope or cardiac arrest, type 1 ECG pattern and first-degree atrio-
ventricular (AV) block were associated with major arrhythmic events; 2) during a 
mean follow-up of 72.6±53.3 months, 20 patients (20.8%) had a total of 38 
appropriate ICD interventions (4%/year) and 26 patients (27.1%) experienced a total 
of 49 adverse ICD-related events (5.4%/year), including 23 inappropriate ICD 
interventions occurring in 9 patients (9.4%) and 26 device-related complications 
requiring surgical revision occurring in 20 patients (20.8%). One patient with end-
stage hypertrophic cardiomyopathy died because of acute heart failure, and 11 
patients underwent heart transplantation. Underweight status was an independent 
predictor of device-related complications; 3) only three patients (4%) had Brugada-
like ECG changes and no patients experienced symptoms or arrhythmic events.  
CONCLUSIONS: In young patients with cardiomyopathies and channelopathies ICD 
therapy provided life-saving protection by effectively terminating life-threatening 
ventricular arrhythmias. However, because ICD-related adverse events are common, 
the risk/benefit ratio should be carefully assessed when considering ICD 
implantation in young people. In addition to traditional risk predictors such as 
previous syncope/cardiac arrest and spontaneous type 1 pattern, we found that 
first-degree AV block was independently associated with a worse outcome in BS. 
FiŶallǇ, ǁe didŶ͛t confirm the high incidence of Brugada ECG-abnormalities 
previously found in a Japanese population with KD. 
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ABBREVIATIONS LIST 
 
Action potential = AP 
Androgen steroid hormone receptor = AR 
Arrhythmogenic right ventricular cardiomyopathy = ARVC 
Antitachycardia overdrive pacing = ATP 
Atrio-ventricular = AV 
Body mass index = BMI 
Brugada syndrome = BS 
Dilated cardiomyopathy = DCM 
Electrophysiological study = EPS 
Hypertrophic cardiomyopathy = HCM 
Idiopathic ventricular fibrillation = IVF 
Implantable cardioverter defibrillator = ICD 
Kennedy͛s disease = KD 
Left-ventricular noncompaction = LVNC 
Long QT syndrome = LQTS 
Programmed ventricular stimulation = PVS 
Right ventricular outflow tract = RVOT 
Short QT syndrome = SQTS 
Subcutaneous ICD = S-ICD 
Sudden cardiac death = SCD 
Ventricular fibrillation = VF 
Ventricular tachycardia = VT 
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BACKGROUND 
 
Sudden cardiac death 
 
Sudden cardiac death (SCD) is defined as an abrupt and unexpected death occurring 
in less than 1 hour from the first symptom onset due to a cardiovascular cause (1). It 
represents a major public health challenge, accounting for 20% of total mortality in 
the industrialised word; almost the half of patients who experience SCD are not 
aware of having a heart disease (2). SCD most often occurs in older adults with 
acquired structural heart disease, but it also rarely happens in the young, where it is 
more commonly due to inherited disorders. The risk of SCD increases with age and is 
more frequent in men. Typically, in young subjects (≤ 35 years), the causes of 
sudden death are mostly cardiovascular; cerebral accidents like subarachnoidal 
haemorrhage due to berry aneurysm rupture and respiratory causes like allergic 
asthma are very rare, accounting for only the 5-7% of all the sudden deaths in the 
young population (3). There are two principal pathophysiologic mechanisms 
underling SCD: a mechanical one, like in case of pulmonary embolism or cardiac 
acute tamponade, and an electric one responsible for more than 90% of the cases of 
SCD due to acute pump failure caused by ventricular fibrillation (VF) or asystole (2). 
Different clinical entities are responsible for SCD in the young and most of them are 
genetic or congenital cardiovascular diseases, while atherosclerotic coronary artery 
disease accounts for the vast majority of fatalities in older subject (>35 years). 
Spontaneous aortic rupture in patients with bicuspid aortic valve or Marfan 
syndrome, congenital anomalies of the coronary arteries, cardiomyopathies like 
arrhythmogenic right ventricular cardiomyopathy (ARVC) or hypertrophic 
cardiomyopathy (HCM), valvular diseases, myocarditis, conduction system disorders 
like Wolff–Parkinson–White syndrome or Lenègre disease, and inherited cardiac ion 
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channel defects (channelopathies) like Brugada syndrome (BS), long QT syndrome, 
short QT syndrome and catecholaminergic polymorphic ventricular tachycardia are 
possible causes of SCD in the young (3). According to the main studies reporting the 
causes of SCD in the young, cardiomyopathies and particularly ARVC and HCM 
account for the majority of the cases: in young athletes, ARVC is responsible for 
approximately one fourth of cases in the Veneto Region of Italy and HCM for more 
than one third of fatal cases in the USA (4-6). A considerable proportion of young 
people who die suddenly have no evidence of structural heart disease and the cause 
of their cardiac arrest in all likelihood is related to a channelopathy. 
Among different series the incidence of SCD in the young varies broadly. The 
difference in SCD rate reported in different studies may be explained by a variety of 
factors, including the age range, the proportion of men and the methodology of 
data collection. The rate of SCD is uncertain, but overall is low. It has been clearly 
demonstrated that participation in sport activity enhances the risk of SCD of 
approximately three times: a prospective study in the Veneto Region of Italy 
reported an incidence of SCD in young people between 12-35 year old of 1 per 
100.000 subject per year from all causes, being 0.9 per 100.000/year in the general 
population and 2.3 per 100.000/year among athletes (4). 
 
Cardiomyopathies and channelopathies 
 
As previous reported cardiomyopathies are a leading cause of SCD among young 
patients and athletes. Their classification evolved in the past decades thanks to the 
great amount of new knowledge in genetic, molecular biology and pathophysiology 
and to the discovery of new clinical entities. The World Health Organization wrote 
the first classification of cardiomyopathies in 1980, based upon the principle to 
distinguish heart muscle diseases in two main groups according to the cause (known 
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or unknown). Cardiomyopathies were considered as ͞heart ŵusĐle diseases of 
uŶkŶoǁŶ Đause͟ and were distinguished according to the predominant structural 
and hemodynamic phenotype in three categories: dilated, hypertrophic and 
restrictive cardiomyopathy. Besides primitive cardiomyopathies, they classified 
speĐifiĐ heart ŵusĐle diseases as ͞heart ŵusĐle diseases of kŶoǁŶ Đause or 
associated with disorders of other systems͟. Cardiac disorders due to systemic or 
pulmonary hypertension, coronary artery, valvular or pericardial disease or 
congenital cardiac anomalies were excluded from both the categories (7). In 1995 
the discovery of new clinical entities brought to a revision of the first classification. 
CardioŵǇopathies ǁere redefiŶed as ͞diseases of the ŵǇoĐardiuŵ assoĐiated ǁith 
ĐardiaĐ dǇsfuŶĐtioŶ͟ and specific heart muscle diseases were named specific 
cardiomyopathies and defined as ͞heart muscle diseases associated with specific 
cardiac or systemic disorder͟. ARVC, left ventricular noncompaction (LVNC) and 
idiopathic restrictive cardiomyopathy were added to the new classification in the 
cardiomyopathy group. In the specific cardiomyopathies group were included 
ŵǇoĐarditis, Đalled ͞iŶflaŵŵatorǇ ĐardioŵǇopathǇ͟, aŶd isĐheŵiĐ, ǀalǀular aŶd 
hypertensive disorders (8). 
The 1995 Task Force report had the merit of recognising new clinical entities and 
including myocarditis as inflammatory cardiomyopathies, but two major concerns 
arise from this new classification. First, the concept of specific cardiomyopathies 
was extended too much to include ischemic, valvular and hypertensive disease and 
this brought ambiguities about the original meaning of cardiomyopathies. Second, 
the idea of dysfunction was limited to the mechanical abnormalities and excluded 
electrical disturbances (9).  
The rapid evolution of genetic and molecular biology in cardiology brought to the 
discovery of gene mutations as the basis of most of the known cardiomyopathies. 
On the other hands, patients suffering rhythm disturbances and SCD presenting 
without any manifest structural abnormalities were recognised to be affected by 
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͞ĐhaŶŶelopathies͟, defiŶed as iŶherited ĐardiaĐ eleĐtriĐ disorder due to mutation in 
ion channels. Although no macroscopic alterations are detectable in 
channelopathies, the structure of myocytes is altered at the molecular level because 
of the presence of mutated proteins. This brought to a necessary revision of the 
1995 WHO classification (9). 
The American Heart Association published a new definition and classification of 
cardiomyopathies in 2006. Cardiomyopathies were defined as ͞a heterogeŶeous 
group of diseases of the myocardium associated with mechanical and/or electrical 
dysfunction that usually (but not invariably) exhibit inappropriate ventricular 
hypertrophy or dilatation and are due to a variety of causes that frequently are 
genetic. Cardiomyopathies either are confined to the heart or are part of generalized 
systemic disorders, often leading to cardiovascular death or progressive heart 
failure–related disability.  
 
Figure 1. Primary cardiomyopathies (Adapted from Maron et al. Circulation 2006 113: 1807-1816). 
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They were divided into 2 groups based on predominant organ involvement. Primary 
cardiomyopathies are those predominantly confined to heart muscle; secondary 
cardiomyopathies show pathological myocardial involvement as part of a large 
number and variety of generalized systemic multiorgan disorders. Among primary 
cardiomyopathies, they recognised 3 subgroups based on the different aetiology: 
genetic, mixed (genetic and non genetic) and acquired (Figure 1). Channelopathies 
or ion channel disorders were included in the genetic group. Cardiac disease 
secondary to other cardiovascular abnormalities like valvular heart disease, systemic 
hypertension, coronary artery disease and congenital heart defect were not 
included in this scheme. 
The AHA classification introduced two important innovations; the first was that the 
classification was no more based on phenotypic expression but on the genetic 
aetiology. The second one was the introduction of the channelopathies among 
primary genetic cardiomyopathies, introducing the concept of a primary electrical 
dysfunction of the heart muscle (10). 
 
Dilated Cardiomyopathy 
 
Definition and epidemiology 
According to the AHA classification, dilated cardiomyopathy (DCM) is included in the 
groups of primary cardiomyopathies with mixed origin and is characterised by the 
presence of left ventricular dilatation and systolic dysfunction in the absence of 
abnormal loading conditions (hypertension, valvular heart disease) or coronary 
artery disease that justify the global systolic impairment (10, 11).  
It has an overall prevalence of 40 cases per 100000 individuals with an annual 
incidence of 7 cases per 100000 individuals and it is more common in men. It 
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represents a leading cause of heart failure and SCD and it is the most common 
indication for heart transplantation (12, 13). 
 
Aetiology 
A pathogenic mutation account for at least 20% of cases of DCM and most 
commonly is inherited as an autosomal dominant trait. The principal mutated genes 
encode for sarcomeric proteins like cardiac troponin T, myosin heavy chain and 
myosin-binding protein C, and for cytoskeletal proteins like lamin A/C or titin. A 
particular X-linked type of DCM is caused by mutations in the dystrophin gene (10-
14). Many acquired conditions are responsible for DCM, including infective agents, 
autoimmune and systemic diseases, toxins (alcohol, cocaine, methamphetamines), 
cytotoxis drugs (anthracyclines) and metabolic disorders. Among infective agents, 
virus like coxsackievirus B, parvovirus B19, human herpes virus 6 and adenovirus are 
often involved in the pathogenesis of DCM (10, 11, 13). 
 
Clinical presentation and diagnosis 
DCM manifest with the typical heart failure symptoms in almost 80% of patients and 
the presentation can be acute and fulminant or chronic. The major causes of 
cardiovascular death are worsening heart failure or SCD secondary to ventricular 
arrhythmia, fatal bradi-arrhythmias or electromechanical dissociation; SCD occurs in 
up to 12% of patients with this disorder and accounts for 25–30% of all deaths (13). 
Diagnosis relies on patient history, and clinical, echocardiographic, or cardiac MRI 
features of dilated cardiomyopathy or heart failure. The definite diagnosis is made 
by the presence of a reduced ejection fraction of the left ventricle (less than 45%) 
and left ventricular enlargement, excluding any myocardial diseases that could be 
responsible for the clinical scenario (12, 13).  
 
Risk stratification and treatment 
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First line therapy is mainly directed at treatment of heart-failure symptoms and at 
prevention of SCD. 
Drugs used in these patients are those that have been shown in large-scale clinical 
trials to improve survival and reduce hospital admissions in heart failure, like 
angiotensin converting enzyme inhibitors, β ďloĐkers aŶd ŵiŶeraloĐortiĐoid 
antagonists (11, 13). Optimal medical therapy is recommended in order to reduce 
the risk of progressive heart failure but also to prevent SCD (11). 
While no doubt exists about the benefit of implantable cardioverter defibrillator 
(ICD) implantation for the prevention of SCD in patients with previous history of 
cardiac arrest or haemodynamically not tolerated sustained VT (11), the evidence of 
the benefit of ICD in primary prevention is less clear. Many non-invasive variables 
have been proposed as predictor of SCD, but the only parameter actually used for 
risk stratification is the degree of left ventricular dysfunction (11). The first 
randomised studies evaluating the benefit of ICD therapy in patients with non-
ischaemic cardiomyopathy with marked reduced ejection fraction, like the SCD-HeFT 
trial or the COMPANION trial, demonstrated a reduction of all-cause death in the 
ICD arm (15, 16). The current Guidelines of the European Society of Cardiology, both 
for heart failure (2016) and for management of patients with ventricular 
arrhythmias and the prevention of SCD (2015), recommend an ICD in patients with 
DCM ͞to reduĐe the risk of suddeŶ death aŶd all-cause mortality in patients with 
symptomatic heart failure (NYHA class II–III), and a left ventricular ejection fraction 
чϯϱ% despite шϯ ŵoŶths of optiŵal ŵediĐal therapǇ, proǀided theǇ are eǆpeĐted to 
survive substantially longer than 1 year with good functional status (class I, level B)͟ 
(11, 17). The Danish study is a randomised trial published in 2016 comparing 
conventional medical treatment with conventional medical treatment plus ICD in 
patients with heart failure and DCM. The main clinical result was the no reduction in 
the primary endpoint of all-cause death for patients randomised to ICD therapy; this 
was despite a significant reduction in sudden cardiac death in the ICD group (18). 
 15 
Taken together all this data highlight the limited value of ejection fraction of the left 
ventricle in risk stratification and underline the need of new and stronger 
parameters for prognostic evaluation in DCM. 
In patients with DCM and recurrent VT refractory to medical therapy, catheter 
ablation is recommended to reduce the incidence of arrhythmic episodes and to 
reduce the number of appropriate ICD intervention (11). 
Heart transplantation and implantation of long-term mechanical circulatory 
supports the final therapy for patients with refractory heart failure (NYHA Class IV) 
(13). 
 
Hypertrophic cardiomyopathy  
 
Definition and epidemiology 
HCM in a genetic primary cardiomyopathy defined by the presence of increased left 
ventricular wall thickness that is not solely explained by abnormal loading conditions 
(12, 20). It is a common inherited heart disease, with a prevalence of at least one in 
500 in the general population and represents a major cause of SCD in the young, of 
heart failure and of atrial fibrillation (19, 21, 22). 
 
Genetics 
In more than a half of the patients with HCM, the disease is an autosomal dominant 
trait caused by mutations in cardiac contractile myofilament protein components of 
the sarcomere or the adjacent Z-disc (19, 20). MutatioŶs iŶ tǁo geŶes, β-myosin 
heavy chain and myosin-binding protein C, account for the majority of cases (23). 
Systemic disorders including inherited metabolic and neuromuscular diseases, 
chromosome abnormalities and genetic syndromes are responsible for the other 
cases of HCM not caused by sarcomeric gene mutations (19).  
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The variability of the phenotypic expression of HCM suggests that the single gene 
mutation is not the only determinant of the clinical phenotype. 
Clinical presentation and diagnosis 
Clinical course of HCM could be very variable, ranging from people that achieve 
normal life expectancy with little or no disability to people who experience high 
morbidity and mortality; the three principal adverse pathways that might occur in 
affected patients are atrial fibrillation, heart failure and SCD due to VT/VF (19, 20).  
Mortality rate in HCM is low, about 1% per year, heart failure and 
thromboembolism being the main causes of death. Nevertheless, HCM is the most 
common cause of SCD in young people and athletes and in most cases SCD occurs in 
asymptomatic subjects without warning sign (19, 20, 22).  
Heart failure with preserved ejection fraction is normally due to diastolic 
dysfunction and small LV size; atrial fibrillation and mitral regurgitation could 
exacerbate symptoms. Evolution of the disease might include decline of the systolic 
function of the left ventricle with end stage heart failure (NYHA III-IV). Structural 
heart changes with progressive cardiac remodelling and myocardial fibrosis are 
usually subclinical in the first stages of the disease and patients could remain 
asymptomatic for long time (19, 20).  Clinical factors correlated with the evolution of 
heart failure are a LV outfloǁ traĐt pressure gradieŶt шϯϬ ŵŵ Hg at rest aŶd the 
diastolic dysfunction (24, 25). 
Atrial fiďrillatioŶs͛ preǀalence is 4-fold greater than in the normal population and is 
associated with worse heart failure symptoms and stroke (26). 
The diagnosis relies on the identification of increased LV wall thickness by any 
imaging modality. According to the 2014 European Guidelines on diagnosis and 
management of hypertrophic cardiomyopathy, ͞iŶ aŶ adult, HCM is defiŶed ďǇ a 
ǁall thiĐkŶess шϭϱ ŵŵ iŶ oŶe or ŵore LV ŵǇoĐardial segŵeŶts—as measured by 
any imaging technique (echocardiography, cardiac magnetic resonance imaging or 
computed tomography) that is not explained solely by loading conditions͟ (20). 
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Risk stratification and treatment 
Multiple risk factors have been used to assess the arrhythmic risk and guide ICD 
therapy in HCM patients in primary prevention, like the presence of non-sustained 
VT, ŵaǆiŵal LV ǁall thiĐkŶess шϯϬŵŵ, faŵilǇ historǇ of “CD, uŶeǆplaiŶed sǇŶĐope, 
and abnormal blood pressure response to exercise. Other clinical characteristics like 
myocardial fibrosis (determined by contrast enhanced CMR), LV apical aneurysms 
and the inheritance of multiple sarcomere protein gene mutations have been 
correlated with an unfavourable arrhythmic outcome (19, 20). The 2014 ESC 
Guidelines on diagnosis and management of hypertrophic cardiomyopathy 
proposed to use the ͞HCM ‘isk-“CD ŵodel͟ to prediĐt the ϱ-year risk of SCD and to 
guide ICD therapy (19, 27). This risk prediction model uses predictor variables that 
have been associated with an increased risk of SCD in at least one published 
multivariable analysis and includes: age, family history of SCD, unexplained syncope, 
left ventricular outflow gradient, maximum left ventricular wall thickness, left atrial 
diameter, NSVT. ICD implantation for primary prevention is recommended in 
patients with an estimated 5-year risk of SCD of more than 6% (high risk group) and 
a life expectancy of >1 year. ICD implantation is not recommended in patients with 
an estimated 5-year risk of SCD of <4% (low-risk group) and no other clinical 
features that are of proven prognostic importance. In patients with an intermediate 
risk (5–year risk 4-<6%) ICD may be considered (19). Finally, ICD implantation is 
recommended in patients who experienced a cardiac arrest due to VT/VF, or who 
have spontaneous sustained VT causing syncope or haemodynamic compromise, 
and have a life expectancy of >1 year (19). 
ICD is the only treatment option with proven effectiveness in preventing SCD, while 
antiarrhythmic drug therapy should be used only for symptom relief (19, 28). 
In the study from Maron et al. conducted in 500 high-risk patients with HCM, the 
incidence rate of appropriate ICD intervention was 10.6%/year in secondary 
prevention and 3.6%/year in primary prevention; 20% of the total population 
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experienced appropriate ICD intervention on VT/VT, while 27% experienced ICD 
related complications including also inappropriate ICD interventions (29).  
A meta-analysis from published studies on outcome and complications after ICD 
therapy in patients with HCM was published in 2012; the annualized rate of 
appropriate ICD interventions was 3.3%, 83% of the population receiving an ICD for 
primary prevention of SCD. The annualized inappropriate ICD intervention rate was 
4.8% and the annualized ICD-related complication rate was 3.4% (30). 
Finally, another study from Maron et al. conducted in 224 children and adolescents 
with HCM judged at high risk, reported an ICD intervention rate of 4.5% per year 
overall, 14% per year for secondary prevention, and 3.1% per year for primary 
prevention. Over a mean follow-up of 4.3±3.3 years, 91 patients (40%) experienced 
at least 1 device-related complication (9.5% per year), particularly inappropriate 
shocks and lead malfunction (31). 
 
Arrhythmogenic right ventricular cardiomyopathy 
 
Definition and epidemiology 
ARVC is an inherited heart muscle disease that predominantly affects the right 
ventricle, classified ad a genetic primary cardiomyopathy. It is characterized 
pathologically by right ventricular myocardial atrophy with fibro-fatty replacement, 
which acts as a substrate of ventricular electric instability with VT or VF that may 
lead to SCD mostly in young people and athletes. Later in the disease course, 
progression of right ventricular muscle disease and left ventricular involvement may 
result in heart failure (32-35).  
It is a rare disease, with a prevalence of 1:5.000 in the general population. The 
disease affects men more frequently than women, with an approximate ratio of 3:1 
and becomes clinically overt most often in the third or fourth decade of age (35). 
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Genetics 
A familial background has been demonstrated in 50% of ARVC cases. The disease is 
usually inherited as an autosomal dominant trait with incomplete penetrance and 
variable expression. It is a desmosomal disease resulting from defective cell 
adhesion proteins (36). The first disease-causing gene, the JUP gene, was identified 
by McKoy et al. in patients with Naxos disease, a particular type of ARVC with a 
autosomal recessive transmission (37). The gene encodes the desmosomal protein 
plakoglobin, a major constituent of cell adhesion junction. Other desmosomal genes 
associated with ARVC with an autosomal dominant inheritance are desmoplakin, 
plakophilin-2 desmoglein-2 and desmocollin-2. Autosomal dominant ARVC has been 
linked to other genes unrelated to cell adhesion complex, such as the gene encoding 
for cardiac ryanodine receptor and the transforming growth factor-β-3 gene. The 
rare ARVC-5 variant, which is characterized by a defect of TMeM43 gene, encoding 
for a transmembrane protein, is associated with a fully penetrant and lethal 
presentation (38). 
 
Clinical presentation and diagnosis 
The clinical phenotype of ARVC varies considerably ranging from asymptomatic 
family members with concealed right ventricular structural abnormalities and no 
arrhythmias to patients experiencing arrhythmic cardiac arrest or undergoing 
cardiac transplantation due to right or biventricular heart failure. The natural history 
of ARVC is predominantly related to ventricular electrical instability, which may lead 
to arrhythmic SCD. In advanced disease, progression of right ventricular muscle 
disease and left ventricular involvement may result in right or biventricular heart 
failure. The following phases in the disease natural history can be considered: 1) 
͞ĐoŶĐealed͟ ĐharaĐterized ďǇ Ŷo or subtle right ventricular structural changes, with 
or without minor ventricular arrhythmias, during which SCD may occasionally be the 
first manifestation of the disease, mostly in young people during competitive sports 
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or iŶteŶse phǇsiĐal eǆerĐise; ϮͿ ͞Oǀert eleĐtriĐal disorder͟ iŶ ǁhiĐh sǇŵptoŵatiĐ 
right ventricular arrhythmias possibly leading to sudden cardiac arrest are 
associated with overt right ventricular functional and structural abnormalities; 3) 
͞right ǀeŶtriĐular failure͟ Đaused ďǇ the progressioŶ and extension of muscle 
disease that provoke global right ventricular dysfunction with relatively preserved 
left ventricular functioŶ. ϰͿ ͞BiǀeŶtriĐular puŵp failure͟ Đaused ďǇ proŶouŶĐed left 
ventricular involvement, mimicking biventricular dilated cardiomyopathy (32-35). 
There is no single test sufficiently specific for diagnosing ARVC, and thus multiple 
criteria are needed. The diagnosis relies on a scoring system based on structural, 
histological, electrocardiographic, arrhythmic, and familial features of the disease. 
The original 1994 International Task Force Criteria have been proposed on the basis 
of the first experience with ARVC patients, who were mostly symptomatic index 
cases with an overt disease and/or sudden death victims (39). Because of the lack of 
sensitivity for identification of minor phenotypes and the absence of quantitative 
cut-off values, these criteria were revised in 2010 to improve diagnostic sensitivity 
while maintaining diagnostic specificity (40). 
 
Risk stratification and treatment 
The role of ICD therapy in patients with overt disease and high risk of SCD (survivors 
from a cardiac arrest and patients with sustained VT) is well established. The first 
study to demonstrate the survival benefit of ICD in ARVC was the Darvin I study (41). 
Patients who received ICD because of cardiac arrest or VT with hemodynamic 
compromise showed a high incidence of VF during follow-up (10% per year of 
follow-up). Clinical predictors of SCD in the subgroup of patients with ARVC who did 
not experience cardiac arrest or VT were investigated by the multicentre 
observational study by Corrado et al. ;͞DarǀiŶ II͟ studǇͿ; theǇ fouŶd that sǇŶĐope 
was the only independent predictor of appropriate ICD interventions (42). Beside 
syncope, different studies identified other predictors of arrhythmic events during 
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follow-up in patients with ARVC e no history of cardiac arrest. The most important 
were the presence of non-sustained VT, dysfunction of the right or left ventricle, 
inducibility at programmed ventricular stimulation (PVS) and the demonstration of 
bipolar RV electroanatomic scar area during endocardial voltage mapping (43, 44). 
The meta-analysis by Schinkel on the efficacy and safety of ICD therapy in ARVC 
patients both for primary or secondary prevention demonstrated a very low annual 
cardiac mortality rate (0.9%) and an annual rate of appropriate ICD intervention of 
9.5%. On the other hands, rates of complications, mostly due to lead failure or 
inappropriate ICD interventions, were respectively of 4.4%/year and 3.7%/year (45). 
During the 2015 International Task Force on the treatment of ARVC (46) indications 
for ICD implantation were formulated (Figure 2). 
 
 
Figure 2. Flow chart of risk stratification and indications to ICD implantation in ARVC (Adapted 
from Corrado et al. Circulation 2015;132:441-53). 
 
 22 
Major risk factors included syncope, non-sustained VT or moderate ventricular 
dysfunction. Minor risks factors were male gender, compound and digenic 
heterozygosity of desmosomal-gene mutations, young age at the time of diagnosis, 
proband status, inducibility at PVS; amount of electroanatomic scar and 
electroanatomic scar-related fractionated electrograms; extent of T-wave inversion 
across precordial and inferior leads; low QRS amplitude and QRS fragmentation. 
Antiarrhythmic drug therapy and catheter ablation are useful to control symptoms 
and reduce ICD discharge, but cannot replace ICD in the prevention of SCD (46). 
Finally, in patients with right or left ventricular dysfunction, standard heart failure 
treatment is recommended (46). 
 
Left-ventricular noncompaction 
 
Definition and epidemiology 
LVNC is a rare genetic primary cardiomyopathy characterised by abnormal 
trabeculations in the left ventricle, most frequently at the apex, creating two distinct 
layers: compacted and non-compacted (47, 48). LVNC may be an isolated finding or 
may be associated with other congenital heart anomalies such as complex cyanotic 
congenital heart disease (49). 
 
Genetics 
Genetic inheritance is found in at least 30-40% of the patients and is most often 
autosomal dominant (49). Usually sarcomeric or cytoskeletal proteins are involved. 
 
Clinical presentation and diagnosis 
Clinical presentation of LVNC is highly variable; some patients could be 
asymptomatic but others may present with end-stage heart failure, lethal 
arrhythmias, SCD, or thromboembolic events. 
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Risk stratification and treatment 
Giving the very low prevalence of the disease risk stratification, treatment and 
indications to ICD implantation should follow the same criteria for DCM (11). 
 
Long QT syndrome 
 
Definition and epidemiology 
Congenital LQTS is an inherited ion channel disease characterised by a prolongation 
of the QT interval at basal ECG and the occurrence of syncope or cardiac arrest due 
to ventricular arrhythmias, mainly precipitated by emotional or physical stress (50, 
51). The prevalence of the disease has been estimated to be 1:2000 (52). 
 
Genetics 
Tree main types of LQTS have been identified based in the disease-causing gene, 
accounting for 90% of all genotype-positive cases. LQTS-1 is caused by a loss of 
function mutation of the potassium channel KCNQ1. Heterozygous KCNQ1 
mutations cause the dominant Romano-Ward LQT-1 syndrome and account for the 
majority of disease-causing variants. Homozygous mutations in KCNQ1, or 
compound heterozygous mutations, cause the recessive Jervell and Lange-Nielsen 
variant, characterized by deafness (51). LQTS-2 is associated with a loss of function 
mutation of the potassium channel KCNH2. The third most common gene is the 
SCN5A gene, encoding for the α-subunit of the cardiac sodium channel: gain of function 
mutations of this protein cause the LQTS-3 (51). 
 
Clinical presentation and diagnosis 
The two fundamental clinical manifestations of the syndrome are the presence of 
ECG abnormalities at the basal ECG (QT prolongation and T wave abnormalities) and 
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of typical symptoms like syncope, cardiac arrest or SCD due to VT. The typical 
ventricular arrhythmia is the ͞Torsades-de-PoiŶtes͟, a rapid polymorphic VT that 
can be self-terminating causing syncope or can degenerate in VF with cardiac arrest 
or SCD (53). According to the genotype, ventricular arrhythmias are triggered but 
different factors. Stress or physical activity induce VT in LQTS-1, Conversely, most of 
the events of LQT2 patients occur during emotional stress such as auditory stimuli 
(sudden noises especially at rest) while for LQT3 patients they occur during sleep or 
at rest (53). 
Diagnosis relies on the measurement of a prolonged correct-QT interval (QTc) on 
surface ECG; secondary causes of QT prolongation must be excluded (drugs, 
electrolyte imbalance, acquired cardiac conditions). According to the 2015 ESC 
Guidelines for management of patients with ventricular arrhythmias and the 
prevention of SCD, the diagnosis is made when there is a QTc ш ϰ80 ms at the basal 
ECG or a LQT“ risk sĐore ш ϯ iŶ the aďseŶĐe of a seĐoŶdarǇ Đause for QT 
prolongation; alternatively, the diagnosis is established when there is an 
unequivocally pathogenic mutation in one of the LQTS genes (11). The scoring 
system predicts the probability of the diagnosis and takes into account the age of 
the patient, medical and family history, symptoms, ECG abnormalities and QTc 
duration (54, 55). 
 
Risk stratification and treatment 
Beta-blockers are the first line therapy for patients with LQTS. In high-risk patients 
symptomatic on beta-blocker therapy or who have contraindications/intolerance to 
beta-blockers, left cardiac sympathetic denervation is recommended; it could be 
also used in case of recurrent ICD interventions despite pharmacological therapy 
(11, 56). Lifestyle changes are also recommended, like avoidance of QT- prolonging 
drugs or of genotype-specific triggers for arrhythmias, correction of electrolyte 
abnormalities (11). 
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Cardiac arrest survivors have a high rate of recurrences of malignant arrhythmias 
even when receiving beta-blocker therapy, so ICD implantation is mandatory (11). 
Arrhythmic risk stratification in patients with LQTS and no previous cardiac arrest is 
based on electrocardiographic, clinical and genetic characteristics. According to the 
2015 ESC guidelines for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death, ICD should be considered in patients 
with syncope during beta-blocker therapy; in asymptomatic carriers, ICD may be 
considered in case of malignant gene mutations when QTc is > 500 ms (11). Of note, 
LQTS is the only channelopathy where the genetic characterisation of the patients 
has an important role in arrhythmic risk stratification. 
A multicentre registry prospectively evaluated 223 patients with LQTS who 
underwent ICD implantation. During a follow-up of more than 4 years, at least 1 
appropriate shock was received by 28% of patients, and adverse events including 
inappropriate ICD interventions or device related complications such as lead failure 
occurred in 25% (57). 
 
Short QT syndrome 
 
Definition and epidemiology 
SQTS is a rare inherited ion channel disease characterised by a shortening of the QT 
interval at basal ECG, SCD and the occurrence of atrial fibrillation; it was first 
described in 2000 (58). 
 
Genetics 
Gain-of-function mutations in genes encoding for potassium channels (KCNH2, 
KCNQ1, KCNJ2) and loss-of-function mutations in gene encoding L-type calcium 
channel subunits (CACNA1C and CACNB2b) have been identified (59). 
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Clinical presentation and diagnosis 
Patients typically present with a short QT interval at basal ECG, history of atrial 
fibrillation at young age and ventricular arrhythmia (59). 
There is still no clear consensus for the definition of the lower limit of the QT 
interval; the ESC guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death suggest 340 ms as cut of 
limit for the diagnosis of SQTS. In case of a confirmed gene mutation, a family 
history of SQTS or SCD and previous cardiac arrest a cut off value of 360 ms could be 
used (11). 
 
Risk stratification and treatment 
ICD implantation is recommended in patients with previous cardiac arrest or 
sustained VT. Given the very low prevalence of the disease clear data on risk 
stratification do not exist, the decision whether to implant or not an ICD should be 
made case by case. 
Quinidine is the only drug that can prolong QT interval and should be used in 
patients who have contraindication to the ICD or refuse it (11). 
 
Idiopathic ventricular fibrillation 
 
IVF is characterized by spontaneous VF in the absence of any identifiable structural 
or functional cardiac disease. The discovery of channelopathies has reduced over 
time the percentage of cardiac arrest without an underlying cardiac disease, 
nevertheless IVF still accounts for a small portion of patients resuscitated from out-
of-hospital cardiac arrest (60). 
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ICD implantation is recommended in these patients. A meta-analysis of the outcome 
of patients with IVF found that 31% of the population experienced a recurrence of 
VT during follow-up (60). 
 
Focus on Brugada Syndrome 
 
Definition, classification and epidemiology 
 
Brugada Syndrome (BS) is a genetic disease with an autosomal dominant inheritance 
pattern and incomplete penetrance; it is characterised by the presence of typical 
electrocardiographic abnormalities, ventricular arrhythmias and increased risk of 
sudden cardiac death (SCD) in the absence of a structural cardiac disease (61-63). 
The first report of the disease was published in 1992 by Josep and Pedro Brugada: 
they described eight patients with recurrent episodes of unexplained aborted 
suddeŶ death preseŶtiŶg ǁith ͞right bundle branch block, persistent ST segment 
elevation in precordial leads not explained by electrolyte disturbances, ischemia or 
structural heart disease͟ (61). Typical ECG abnormalities both of repolarisation and 
of depolarisation are the hallmark of this syndrome; three electrocardiographic 
repolarization patterns in the right precordial leads are described (Figure 3). Type 1 
(coved-type) is characterized by a prominent coved ST-segment elevation displaying 
J wave amplitude or ST-segment elevation ш 2 mm (0.2 mV) followed by a negative T 
wave with little or no isoelectric separation in ш 1 right precordial lead (V1-V3) 
(Figure 3). Type 2 (saddleback-type) has a high take-off ST-segment elevation, with 
the J wave amplitude ш 2 mm, giving rise to a gradually descending ST-segment 
elevation (remaining ш 1 mm above the baseline), followed by a positive or biphasic 
T-wave. Type 3 has either a saddleback or coved appearance with an ST-segment 
elevation of <1 mm. These 3 patterns may be observed spontaneously at different 
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time in serial ECG tracings from the same patient or after the introduction of specific 
drugs. These ECG patterns are usually detected by positioning the right precordial 
leads in the fourth intercostal space; the placement of the right precordial leads in a 
superior position (in the second or third intercostal space) can increase the 
sensitivity of the ECG for detecting the Brugada phenotype in some cases (64, 65). 
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Figure 3. Three electrocardiographic repolarization patterns in the right precordial leads in 
Brugada syndrome (Adapted from Mizusawa et al. Circ Arrhtthm Electrophysiol 2012; 5(3):606-16). 
 
ECG characteristics include also depolarisation abnormalities like conduction 
disturbances, pronounced S waves in the inferior leads creating the typical S1S2S3 
pattern and atrio-ventricular (AV) first-degree block. Typical clinical manifestations 
of the syndrome include unexplained cardiac arrest, documented ventricular 
tachycardia, syncope and nocturnal agonal respiration; atrial fibrillation has higher 
prevalence in these patients.  
BS is included in the ͞Contemporary definitions and Classification of 
Cardioŵyopathies͟ published in 2006 under the auspices of the American Heart 
Association (10). During the decades before the publication of this consensus panel, 
the identification of new pathological entities and the important advantages in the 
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pathophysiology, diagnosis and therapy in this field brought to the need of a more 
rigorous definition and classification of cardiomyopathies. Particularly, the new 
molecular genetics knowledge in cardiology allowed the discovery of the ion 
channelopathies, like BS; they are defined as cardiomyopathies predisposing to 
ventricular tachyarrhythmia and SCD in the absence of functional and structural 
myocardial abnormalities. Channelopathies are primary electrical disease, caused by 
mutations in ion channel proteins leading to dysfunctional sodium, potassium, 
calcium, and other ion channels; they are classified like primary genetic 
cardiomyopathies (Figure 1). 
BS is more frequent and with a worse prognosis in male than in female (M:F = 10:1) 
(66); it affects normally young men during adulthood, with a mean age of sudden 
death of 41±5 years (62). It accounts for at least 4% of all sudden deaths and at least 
20% of sudden deaths in patients with structurally normal hearts. The true 
prevalence of the disease is difficult to estimate, because of the dynamic presence 
of the ECG pattern in the same subject in different moment and because of the 
different geographic distribution, being the syndrome endemic in Asian countries. 
The global prevalence of Brugada syndrome varies from 5 to 20 cases in every 
10,000 inhabitants worldwide. In a Japanese study of 2001, a Brugada diagnostic 
ECG (type 1) was observed in 12/10000 inhabitants; type 2 and 3 ECGs (not 
diagnostic), were much more prevalent, appearing in 58/10000 inhabitants; the 
prevalence of the BS among the general population in Europe and the United States 
is thought to be much lower (62, 67). 
 
Genetic basis 
 
 
In 1998, Chen et al. found the first mutation linked to BS in the SCN5A gene, which 
encodes for the α-subunit of the sodium channel protein Nav1.5 (68). 
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since then, more than 300 SCN5A gene mutations have been identified in BS 
patients.  
 
Table 1. Gene defects associated with Brugada Syndrome (modified from Antzelevitch et al. 
Europace 2017; 19(4): 665-94). 
 
Gene/protein Ion Channel Percent of probands 
SCN5A, Nav1.5  INa 11-28% 
GPD1L  INa Rare 
CACNA1C, Cav1.2  ICa 6.6% 
CACNB2b, Cavβ2b  ICa 4.8% 
SCN1B, Navß1  INa 1.1% 
KCNE3, MiRP2  Ito Rare 
SCN3B, Navß3  INa Rare 
KCNJ8, Kir6.1  IK-ATP 2% 
CACNA2D1, Cava2d1  ICa 1.8% 
KCND3, Kv4.3  Ito Rare 
RANGRF, MOG1  INa Rare 
SLMAP  INa Rare 
ABCC9, SUR2A  IK-ATP Rare 
SCN2B, Navß2  INa Rare 
PKP2, Plakophillin-2  INa Rare 
FGF12, FHAF1  INa Rare 
SCN10A, Nav1.8  INa 5-16.7% 
HEY2   INa Rare 
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SCN5A mutations cause loss-of-function of the sodium channel Nav1.5 resulting in a 
reduction in INa current with different mechanisms: decreased expression of the 
sodium channel protein in sarcolemma, expression of non-functional channels, or 
altered gating properties (delayed activation, earlier inactivation, faster inactivation, 
enhanced slow inactivation, and delayed recovery from inactivation).  
SCN5A loss-of-function mutations may cause not only BS but also may lead to other 
diseases, like progressive cardiac conduction disease, Lenegre disease and sick sinus 
syndrome; SCN5A gain-of-function mutations contribute to the development of 
atrial fibrillation and long-QT-syndrome (65, 69, 70).  
SCN5A mutations are the most common type in BS, accounting for 11–28% of BS 
probands, but to date mutations in 18 different genes have been associated to BS, 
most of all encoding for ionic channels protein (70) (Table 1).  
Mutations in genes encoding the proteins of the calcium channels CACNA1C 
(Cav1.2), CACNB2b (Cavβ2b) and CACNA2D1 (Cavα2δ) have been reported in up to 
13% of probands; these mutations cause a loss of function of basal L-type calcium 
current (65, 71-73). Patients with mutations into CACNA1C and CACNB2b generally 
present with shorter-than-normal QT intervals (73). Other genes have been 
associated more rarely to BS, like sodium channel β-subunit genes (SCN1B, SCN3B), 
glycereol-3 phosphate dehydrogenase 1-like enzyme (GPD1L) and MOG1, and genes 
encoding for potassium channels (KCNE3, KCND3) (74-77). Mutations in SCN1B, 
SCN3B, GPD1L, or MOG1 genes led to loss of function of the sodium current; 
mutations in the potassium channel proteins bring to a gain of function of the 
transient outward potassium currents (65,70). One of the most recent gene 
associated with BS is the SCN10A, a neuronal sodium channel; mutations in this 
gene are responsible for a loss of function in sodium (INa) and calcium (ICa) channel 
currents, as well as to a gain of function in transient outward potassium current (Ito) 
or ATP-sensitive potassium current (IK-ATP) (78, 79). Despite the great amount of data 
on the genetic background of BS, studies proving the causality between a gene 
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mutation and BS are still lacking. In most cases gene mutation alone cannot 
completely explain the phenotype and may act mostly as modifiers rather than 
cause. Data from genetic studies have brought to the concept that BS phenotype is 
the results of inheritance of multiple BS susceptibility variants acting in concert; 
moreover, the complexity of the genetic predisposition can be modulated by non-
genetic factors, like hormonal and other environmental factors (70, 80).  
 
Physiopathology and arrhythmogenesis 
 
Over the paste decades, the pathophysiological mechanism underling the ECG 
features and the arrhythmogenesis in BS has been investigated but it still remains a 
matter of debate. Two leading hypotheses have been advanced, the repolarization 
hypothesis and the depolarization hypothesis. 
 
The repolarization hypothesis  
To understand the cellular basis of electrocardiographic J wave and of 
arrhythmogenesis in BS according to the repolarization hypothesis, it is necessary to 
know the basic principles of cardiac electrophysiology. The cardiomyocyte cell 
membrane is a hydrophobic milieu made of lipids, so ions, that are hydrophilic, 
cannot directly cross it and need specialized proteins, the ion channels, to penetrate 
the cell membrane; most cardiac ion channel are both time and voltage dependent. 
The action potential (AP) begins when the transmembrane potential of the 
cardiomyocytes become more positive; in response to this signal the sodium 
voltage-depeŶdeŶt ĐhaŶŶels Naǀϭ.ϱ ŵoǀe froŵ the ͞Đlosed͟ ĐoŶfiguratioŶ to the 
͞aĐtiǀated͟ ĐoŶfiguratioŶ, geŶeratiŶg the iŶǁard sodiuŵ ĐurreŶt ;INa) responsible for 
the depolarizatioŶ ͞phase Ϭ͟ of the AP ;Figure ϰ). The rapid cell depolarization 
activates potassium and calcium channels and brings the sodium channels to the 
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͞iŶaĐtiǀated͟ forŵ. DuriŶg the ͞phase ϭ͟ of the AP Đalled earlǇ repolarizatioŶ aŶ 
outward potassium current (Ito) is responsible for a rapid and short deflection 
(notch) of the AP. The rapid cell depolarization activates potassium and calcium 
ĐhaŶŶels aŶd ďriŶgs the sodiuŵ ĐhaŶŶels to the ͞iŶaĐtiǀated͟ forŵ. DuriŶg the 
͞phase ϭ͟ of the AP Đalled earlǇ repolarizatioŶ aŶ outǁard potassiuŵ ĐurreŶt ;Ito) is 
responsible for a rapid and short deflection (notch) of the AP. 
 
–
–
 
 
 
 
16–
 
 
–  
 
 
 
 
   
INa
Ito
ICaL
IKr
IK1
INCX
IKs
Channelα-subunit
Nav1.5
Kv4.3
Cav1.2 
Kv11.1
(hERG)
Kv7.1
(KvLQT1)
Kir2.1–2.3
NCX
4 4
30
1
2
 
 
 
   
 
    –
β β
α 
β 
© 2014 Macmillan Publishers Limited. All rights reserved
 
Figure 4. The cardiac action potential and the major contributing cardiac ion channel currents 
(Adapted from Liu et al. Nat Rev Cardiol 2014; 11(10): 607-15).  
 
The activity of the L-type calcium channels is respoŶsiďle for the ͞phase Ϯ͟ or 
plateau phase of the AP, where the outward repolarising potassium currents (IKs and 
IKr) are balanced by the inward depolarising calcium current. Finally, during the 
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͞phase ϯ͟ or repolarization phase the calcium channels are gradually inactivated and 
the outflow of potassium exceed the inflow of calcium, brining the membrane cell to 
the resting potential.  
The notch in the phase 1 of the AP is much more accentuated in the epicardium of 
the right ventricular outflow tract (RVOT), where the Ito current is more abundant, 
compared to the intermediate M cells and the endocardium, giving rise to more 
prominent Ito-mediated spike-and-dome AP morphology in ventricular epicardium. 
The more conspicuous notched configuration of the epicardial response is thought 
to produce a transmural voltage gradient responsible for the genesis of the J wave 
and J point elevation on the surface ECG (81). In healthy people, J wave is frequently 
small and merged in the QRS; the ST segment is isoelectric due to the absence of 
transmural voltage gradient during the phase 2 of the AP (Figure 5).  
 
 
Figure 5. Normal transmembrane action potential and surface ECG (Adapted from Antzelevitch C. J 
Cardiovasc Electrophysiol 2001; 12(2): 268-272). 
 
In Brugada patieŶts͛ loss of function mutations of the sodium channel Nav1.5 lead to 
a reduction of the inward sodium current (INa), living the Ito current unopposed in the 
phase 1 of the AP; this current shift accentuates the notch of the epicardium AP but 
not in the endocardium AP, giving reason of a greater transmural voltage gradient 
and a more accentuate J wave and ST segment elevation on the surface ECG. This 
happens because in the RVOT epicardium the Ito current is much more prominent 
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respect to the RVOT endocardium. The phase 1 of the AP is a result of al least 3 
currents (INa, Ito e ICa); mutations of ion channels provoking an outward shift in the 
balance of currents are able to produce the same effect of the loss of function 
mutations of the sodium channel Nav1.5. 
If the epicardial repolarization continues normally, preceding the repolarization of 
the M-cells and of the endocardium, the T wave remains positive and the surface 
ECG assume a saddleback configuration (Figure 6) (82). 
 
 
Figure 6. Action potential and surface ECG in patients with Brugada Syndrome and a Saddleback 
configuration (Adapted from Antzelevitch C. J Cardiovasc Electrophysiol 2001; 12(2): 268-272). 
. 
 
 
Figure 7. Action potential and surface ECG in patients with Brugada Syndrome and a coved-type 
configuration (Adapted from Antzelevitch C. J Cardiovasc Electrophysiol 2001; 12(2): 268-272). 
 
If there is a prolongation of the epicardial AP reversing the direction of the 
repolarization across the right ventricular wall, the ST segment elevation is followed 
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by a negative T wave and the surface ECG assumes a coved type configuration 
(Figure 7) (82). 
The current imbalance, coming from a reduction of the outward sodium or calcium 
current or the implementation of the potassium inward current, is responsible also 
for the loss of the AP dome morphology in some epicardial site, causing a marked 
shortening of the AP in some epicardial cell but not in all, leading to both a 
transmural and intra-epicardial pronounced dispersion of repolarization. Moreover, 
the dysfunction of the sodium channel impairs the conduction of the current 
impulse and creates conduction blocks. The loss of the AP dome in epicardium, the 
consequent shortening of the refractory period in some cells but not in all and the 
presence of conduction block are the basis for the micro-reentry between cells; it 
creates a vulnerable window during which an ectopic beat can induce a reentrant 
arrhythmia (Figure 8). This arrhythmogenesis ŵeĐhaŶisŵ is Đalled ͞phase Ϯ reentry͟ 
and can induce VF.  
 
 
 
Figure 8. Loss of dome of the epicardial action potential and phase 2 reentry (Adapted from 
Antzelevitch C. J Cardiovasc Electrophysiol 2001; 12(2): 268-272). 
 
In conclusion, Antzelevitch et al. demonstrated that the basis for ECG abnormalities 
and arrhythmogenesis in BS is an outward shift of net transmembrane current at the 
end of the phase 1 of the AP in the epicardium, where the Ito current is most 
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prominent, but not in the endocardium. This cause an accentuated spike and dome 
morphology of the AP in epicardium, a voltage gradient between epicardium and 
endocardium during phase 1 of the AP and in some epicardial cells also the loss of 
the AP dome and the abbreviation of the AP duration. There is both a voltage 
gradient between endocardium and epicardium and between different epicardial 
cells with different AP duration. Ectopic beats that find some epicardial cells in a 
vulnerable phase because of their short AP can induce reentrant arrhythmias and 
VF. The reason why only some epicardial cells lose the dome morphology in 
response to mutations of the ions channels proteins is a heterogeneous expression 
of the Ito current (83, 84). This hypothesis is consistent with the evidence that BS is 
associated with loss of function mutations of sodium and calcium channels and with 
gain of function mutations of potassium channels (81, 82, 85).  
This fascinating theory coming from experimental studies lack of strong clinical 
relevant proofs and that brings to the development of other pathogenesis 
hypothesis. 
 
The depolarization hypothesis  
The depolarization hypothesis suggests that a conduction delay, particularly in the 
RVOT, is the basis of arrhythmogenesis in BS. In connection with the conduction 
delay, there are evidences of ultra-structural abnormalities in the right ventricle of 
Brugada patients that may be responsible for the presence of slow conduction areas 
(86). These mild structural changes, like fibrosis, are not detectable with the 
conventional imaging tools (echocardiography, magnetic resonance) but were found 
in an explanted heart or in biopsies of BS (87, 88). According to the depolarization 
hypothesis, the RVOT is the last to depolarize; the delay in the AP of the RVOT 
generates a gradient from the most positive RV and the RVOT that generates an ST-
segment elevation in the right precordial leads. The gradient is reversed during 
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repolarisation resulting in a negative T wave on the surface ECG of the same right 
precordial leads (69).  
Most of the evidences supporting this theory come from clinical studies. The first 
evidence comes from Nagasa et al: they found abnormal electrograms with late 
potentials after QRS recording from the epicardium of the RVOT (89). The report 
from Nademanee et al gave strong clinical evidence of this hypothesis; they studied 
9 patients with BS and recurrent VF; they recorded abnormal prolonged ventricular 
electrograms and abnormal low voltage fractionated electrograms in the epicardium 
of the RVOT of these patients. The ablations of these potential brought to ECG 
normalisation and rendered ventricular arrhythmias no more inducible (90). 
 
Both the theories agree about the origin of the ventricular arrhythmias in BS, 
coming surely from the RVOT. Although in the past decades many studies brought 
new insight in the pathogenesis and arrhythmogenesis of BS, both the repolarization 
and the depolarization hypothesis are not able to fully explain the disease. 
 
Clinical presentation 
 
BS is characterised by the presence of a typical ECG pattern and malignant 
ventricular tachyarrhythmia. Syncope, agonal respiration and cardiac arrest are the 
typical clinical manifestations. The first two symptoms are caused by self-
terminating ventricular arrhythmias; cardiac arrest is due to VF. Patients may remain 
asymptomatic for a long period and in some cases cardiac arrest due to VF is the 
first and only clinical manifestation of the disease. Brugada patients are relatively 
young, between 20 and 40 years old; there is a 10-fold higher prevalence in male 
than in female, despite an autosomal dominant inheritance pattern. BS is 
responsible for 4-12% of all SCA and for 20% of SCD in patients with structurally 
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normal heart. The mean age of patient presenting with VF is 41 ± 15 years. 
Arrhythmic events occur predominantly in men (5.5-fold risk of SCD compared with 
women), during the night, at rest or while asleep, ventricular arrhythmias are not 
triggered by sport activity. Patients may report palpitations: typically, these are due 
to atrial fibrillation, which has a higher prevalence (11-14%)in Brugada patients (62, 
64, 65, 69). 
 
Diagnosis 
 
Diagnostic Criteria 
The last version of the diagnostic criteria was published in 2013 in the consensus 
statement on inherited primary cardiac arrhythmias syndromes and in 2015 in the 
guidelines for the management of patients with ventricular arrhythmias and 
prevention of SCD. They affirmed that ͞B“ is diagnosed in patients with ST- segment 
elevation with type 1 morphologǇ шϮ ŵŵ iŶ шϭ lead aŵoŶg the right preĐordial 
leads V1, V2, positioned in the 2nd, 3rd or 4th intercostal space occurring either 
spontaneously or after provocative drug test with intravenous administration of 
Class I antiarrhythmic drugs. BS is diagnosed in patients with type 2 or type 3 ST-
segŵeŶt eleǀatioŶ iŶ шϭ lead aŵoŶg the right preĐordial leads Vϭ, VϮ positioŶed iŶ 
the 2nd, 3rd or 4th intercostal space when a provocative drug test with intravenous 
administration of Class I antiarrhythmic drugs induces a type I ECG morphology͟ (11, 
56). The J-wave syndrome expert consensus conference held in Shanghai in 2017 
recommend that when a type 1 Brugada ECG pattern is unmasked using a 
provocative drug test, the diagnosis of BS should be made only if there are 1 of the 
following criteria: documented VF or polymorphic VT, syncope of probable 
arrhythmic cause, a family history of SCD at 45 years old with negative autopsy, 
coved-type ECGs in family members, or nocturnal agonal respiration. They also 
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proposed a diagnostic score system, called the ͞Proposed Shanghai Brugada 
Syndrome Score͟; the diagŶosis of B“ is proďaďle/defiŶite ǁith ш ϯ.ϱ poiŶts, possiďle 
with 2-3 points and non diagnostic if there are less than 2 point. In Table 2 we 
reported the clinical variable and the corresponding points (70). 
 
Table 2. Proposed Shanghai Score System for diagnosis of Brugada syndrome (modified from 
Antzelevitch et al. Europace 2017; 19(4): 665-94). 
 
CLINICAL VARIABLES POINTS 
I. ECG (12-Lead/Ambulatory)*  
A. Spontaneous type 1 Brugada ECG pattern at nominal or high leads 3.5 
B. Fever-induced type 1 Brugada ECG pattern at nominal or high leads 3 
C. Type 2 or 3 Brugada ECG pattern that converts with provocative drug challenge 2 
II. Clinical History**  
A. Unexplained cardiac arrest or documented VF/ polymorphic VT 3 
B. Nocturnal agonal respirations 2 
C. Suspected arrhythmic syncope 2 
D. Syncope of unclear mechanism/unclear etiology 1 
E. Atrial flutter/fibrillation in patients < 30 years without alternative etiology 0.5 
III. Family History**  
A. First- or second-degree relative with definite BS 2 
B. Suspicious SCD (fever, nocturnal, Brugada aggravating drugs) in a first- or second-
degree relative 
1 
C. Unexplained SCD < 45 years in first- or second- degree relative with negative 
autopsy 
0.5 
IV. Genetic Test Result  
A. Probable pathogenic mutation in BS susceptibility gene 0.5 
*Only award points once for highest score within this category. One item from this category must apply. **Only award points once for highest 
score within this category. BS=Brugada syndrome; SCD= sudden cardiac death; VF= ventricular fibrillation; VT=ventricular tachycardia. 
 41 
Pharmacologic test 
The ECG alterations in Brugada patients are dynamic and concealed, so they need to 
be unmasked with a provocative test. At the basis of the electrocardiographic 
pattern there is a current imbalance during the AP with a reduction of the net 
outward current. Provocative pharmacological test is for this reason performed with 
sodium channel blockers (ajmaline, flecainide, procainamide, pilsicanide), which 
accentuate the genetic defect. It is recommended in patients where there is a 
clinical suspicion of BS in the absence of a spontaneous type 1 ECG; it should not be 
performed in case of asymptomatic patients with a spontaneous type 1 ECG because 
of the lack of additional diagnostic value. The test is considered positive a type 1 
Brugada ECG pattern is induced; it must be interrupted in case of sustained 
ventricular arrhythmias or widening of the QRS > 130% of the baseline value. 
Because of the possibility of severe complications (ventricular arrhythmias, 
mechanoelectrical dissociation), the test should be performed und close monitoring 
with continuous ECG monitoring and full equipment for resuscitation (62, 64, 70). 
 
Genetic Test 
Because of the complex and heterogeneous genetic background, genetic test has a 
very limited role in the diagnosis of BS. SCN5A variants account only for 18%-28% of 
patients and other 17 genes are associated with BS. As previous reported, genetic 
alone cannot explain the phenotype. Probst et al. analysed 13 families with SCN5A 
mutation and the genotype did not co-segregate with the phenotype; some family 
members showing BS phenotype did not have the familial SCN5A mutations and 
mutation carriers do not have a diagnostic Brugada ECG (91). As reported in the 
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the 
Channelopathies and Cardiomyopathies in 2011, genetic test is not involved in the 
diagnosis of the disease. They recommend to do genetic test in particular situations:  
1) genetic testing can be useful for any patient in whom a cardiologist has 
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established a clinical index of suspicion for BS based on examiŶatioŶ of the patieŶt͛s 
clinical history, family history, and expressed electrocardiographic (resting 12-lead 
ECGs and/or provocative drug challenge testing) phenotype; 2) genetic testing is not 
indicated in the setting of an isolated type 2 or type 3 Brugada ECG pattern; 3) 
mutation-specific genetic testing is recommended for family members and 
appropriate relatives following the identification of the BS-causative mutation in an 
index case (92). In asymptomatic mutation carriers it is very important to perform a 
strict follow-up and to advised the subject to prevent and correct hypokalaemia, to 
promptly treat a fever >38° by antipyretic therapy, and to use caution in taking 
antiarrhythmic drugs known to worsen ECG abnormalities and potentially trigger 
VT/VF in BS (92). 
 
Differential diagnosis 
Before confirming the diagnosis of BS, other causes of ST elevation in the right 
precordial lead should be excluded.  The J-wave syndrome expert consensus 
conference proposes a list of condition that must be considered as alternative 
diagnosis when we are facing patients with St-segment elevation in right precordial 
leads. These are:  atypical right bundle branch block; ventricular hypertrophy; early 
repolarization (especially in athletes); acute pericarditis/myocarditis; acute 
myocardial ischemia or infarction (especially of the right ventricle); pulmonary 
thromboembolism; Prinzmetal angina; dissecting aortic aneurysm; central and 
autonomic nervous system abnormalities; Duchenne muscular dystrophy; Friedreich 
ataxia; spinobulbar muscular atrophy; myotonic dystrophy; arrhythmogenic right 
ventricular cardiomyopathy (ARVC); mechanical compression of the right ventricular 
outflow tract (e.g. pectus excavatum, mediastinal tumor, hemopericardium); 
hypothermia; post-defibrillation ECG (70). Particularly challenging is the differential 
diagnosis with ARVC. ARVC is a genetic cardiomyopathy that predominantly affects 
the right ventricle. It is characterized pathologically by RV myocardial atrophy with 
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fibro- fatty replacement, which acts as a substrate of ventricular electric instability 
leading to malignant ventricular tachyarrhythmia. Molecular genetic has provided 
new insights in understanding the pathophysiology of ARVC, showing that it is a 
desmosomal disease resulting from defective cell adhesion proteins (44). There are 
similarities in the phenotypic expression of the two diseases. Both of them affect 
the RVOT, manifest with syncope and cardiac arrest due to ventricular tachycardia 
and presents typical ECG abnormalities in the right precordial leads like T wave 
inversion or conduction disturbances. Particularly in the concealed phase of ARVC, 
characterized by no or subtle right ventricular structural changes, it could be hard to 
distinguish the two clinical entities (70).  
 
Risk stratification 
 
BS is a channelopathy associated with increased risk of SCD among young people 
and ICD is the only effective therapeutic strategy to prevent this tragic event. Risk 
stratification is challenging particularly in asymptomatic patients, where the risk of 
malignant arrhythmic events during follow-up is very low but not zero and sudden 
death could be the first and only manifestation of the disease. Because of the low 
prevalence of the disease and the low events rate, it is very difficult to find strong 
predictors of fatal arrhythmic outcome. Considering the relative high incidence of 
complications of ICD therapy and its negative impact on quality of life and 
morbidity, the decision whether to implant an ICD in a Brugada patient should be 
precede by an accurate risk assessment, balancing possible advantages and 
complications. 
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Clinical manifestations: syncope, cardiac arrest and asymptomatic patients 
Cardiac arrest survivor presenting with a Brugada ECG pattern are at very high risk 
of fatal events recurrence during follow-up; in this particular subset of patient ICD 
implantation has a Class I indication (70).  Data from different studies support this 
recommendation. The rate of recurrent arrhythmic events among cardiac arrest 
survivors was 7.7% per year in the FINGER registry (93); in patients in whom the ICD 
therapy indication was aborted SCD, appropriate device therapy rate at 7 years was 
44% in the study from Conte et al (94) and at 10 years was 48% in the study from 
Sacher et al (95).  
Syncope is a typical clinical manifestation of BS but its underling mechanism could 
be different and also its prognostic value (96). Non-arrhythmic syncope is normally 
of vaso-vagal origin, presenting with prodromes and with a recognised trigger; 
patients with this type of syncope have a good prognosis. On the contrary in case of 
malignant syncope, neither prodromes nor specific trigger are present, suggesting 
that the syncope is due to a self-terminating ventricular arrhythmia. In this case the 
prognosis is unfavourable and there is a strong indication for ICD implantation (70). 
The annual cardiac event rate of patients with syncope was 1.9% in the FINGER 
study (93) and 3% in the study from Delise et al (97); in many studies syncope was 
found to be an independent predictor of malignant arrhythmic events during follow-
up (93, 95, 97-99). 
All the studies above mentioned confirm the good prognosis of patients presenting 
with a Brugada ECG pattern without typical symptoms. In asymptomatic patients 
the cardiac event rate per year is very low and varies between was 0.5% and 1% (93, 
95, 97).  
Established that in case of a clinical presentation with cardiac arrest, ventricular 
arrhythmia and syncope there is a clear indication for ICD implantation because of a 
high rate of recurrences of cardiac arrhythmic events during follow-up, the decision 
for a prophylactic ICD in asymptomatic subject is still a matter of debate.  Many 
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efforts have been made in finding predictors of a poor arrhythmic outcome in this 
low-risk class of patients, analysing the prognostic value of gender, family history, 
genetic predisposition, ECG abnormalities and inducibility at electrophysiological 
study (EPS).  
 
Gender, family history and genetic predisposition 
In the Finger study they proved that gender, family history of SCD, and presence of a 
mutation in the SCN5A gene have no predictive value (93). Also Delise et al. found 
that male gender and family history of SCD conferred an increased risk, but they do 
not reach a statistical significant power (97). Until now, only one study has 
demonstrated that some SCN5A mutations leading to premature truncation of the 
protein bring to a more severe phenotype than missense mutations of the same 
protein (100). This is an important evidence of the possible role of genetic testing in 
risk stratification in BS. Nevertheless, there are insufficient data to allow the use of 
routinely genetic testing for prognostic use. 
 
Electrophysiological study 
The role of EPS in risk stratification in BS is still under debate.  The study from 
Brugada et al. demonstrated that in Brugada patients with no history of previous 
cardiac arrest the inducibility of a sustained ventricular arrhythmia was a predictor 
of events in the multivariate analysis (99). On the contrary, in the FINGER study 
inducibility of sustained ventricular arrhythmia during EPS was not predictive of 
arrhythmic events (93). The study of Delise et al. highlighted the role of EPS in the 
risk stratification as an addiction variable that should be considered only together 
with other clinical risk factors; particularly they found that EPS has a 100% negative 
predictive value, so it could help in identify subjects at low risk (97). The PRELUDE 
study is a prospective registry, designed to assess the predictive accuracy of 
inducibility of sustained VT/VF in Brugada patient with no previous history of 
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sustained ventricular arrhythmia/cardiac arrest; they found that inducibility at EPS 
was not a predictors of events during follow-up. Of the contrary, they demonstrated 
that a ventricular refractory period < 200 ms is a strong predictors of arrhythmic 
events during follow-up (98). The discrepancy between the above-mentioned 
studies relies probably on two major factors: the differences in the programmed 
ventricular stimulation protocol (number of extrastimuli, site of stimulation) and in 
the basal population. 
 
Repolarization and depolarization abnormalities 
Among all ECG abnormalities, the presence of a spontaneous type I Brugada ECG 
pattern at the time of the diagnosis is the most powerful predictor of arrhythmic 
events during follow-up (93, 97, 98). In addition, both depolarization and 
repolarization ECG abnormalities offer the potential to refine the risk stratification 
in BS and their prognostic value have previously reported. Conduction abnormalities 
like the prolongation of PR interval (101), the increase of QRS duration (102, 103), as 
well as the presence of left anterior fascicular block (101) and right bundle branch 
block (104) confer an increased arrhythmic risk. In the PRELUDE study, not only the 
presence of a spontaneous type I ECG but also the evidence of a fragmented QRS 
(defined as 2 or more spikes within the QRS complex in leads V1 to V3) was 
significant predictors of arrhythmias during follow-up (98). Recently, it has been 
demonstrated that the presence of a wide and/or large S wave in lead I is an 
independent predictor of ventricular arrhythmias during follow-up (105). 
Repolarization abnormalities found to be markers of increased arrhythmic risk are 
the prolongation of QT interval (106, 107), the presence of T-waves alternans (107) 
and the pattern of early repolarization in the inferior and lateral leads (106, 108-
110). 
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Therapy 
 
Treatment options in BS include lifestyle changes, antiarrhythmic drug therapy, 
catheter ablation of the RVOT and ICD implantation. In figure 9 are graphically 
represented the recommendations for management and treatment of Brugada 
patients. 
 
Figure 9. Recommendations for therapy according to the J-Wave syndromes expert consensus 
conference report (modified from Antzelevitch et al. Europace 2017; 19(4): 665-94). 
 
Lifestyle changes include prompt treatment of fever and avoidance of drugs and 
toxins that can exacerbate the typical ECG abnormalities and induce VT (70). 
Among antiarrhythmic drugs, amiodarone and Class IC agents are respectively 
ineffective and contraindicated. The only antiarrhythmic drug able to normalize ECG 
and reduce ventricular arrhythmia is quinidine, because of its ability to inhibit the Ito 
current; both experimental models and clinical data support the effectiveness of 
quinidine in this setting. Unfortunately, selective inhibitors of the Ito current are not 
available. Quinidine is indicated in patients with recurrent appropriate ICD 
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interventions and if ICD is refused or contraindicated (70). In case of electrical 
storm, beta-adrenergic agents such as isoproterenol are useful (70). 
Different studies reported the efficacy of ablation of late and fragmented epicardial 
potentials of the RVOT in reducing arrhythmic recurrences and normalising the ECG 
pattern (90, 116). Ablation may de considered in case of recurrent ICD shocks (70). 
ICD is the only proven life saving therapy in patients with BS at high risk for SCD. The 
available literature and the clinical experience of the task force members of the 
Shanghai conference allow the following recommendation for ICD therapy. ICD 
implantation is recommended in case of: 1) aborted SCD or documented VT/VT 
(Class I), 2) syncope likely caused by VT/VF in patients with a diagnostic Brugada ECG 
(Class IIa), 3) inducibility of VF at PVS (Class IIb). 
ICD therapy is not free from complication, given the considerable incidence of 
adverse events like inappropriate ICD interventions and lead failure. In the study 
from Sacher et al., rates of inappropriate shock and lead failure at 10 years were 
37% and 29%, respectively (95). Conte et al. found that 33 (18.7%) patients had 
inappropriate shocks and 28 (15.9%) patients had device-related complications (93). 
 
Kennedy Disease 
 
Spinal and bulbar muscular atrophy, also kŶoǁŶ as KeŶŶedǇ͛s disease ;KDͿ, is a rare, 
slowly progressive, neuromuscular disorder. It is caused by a mutation in the first 
exon of the androgen steroid hormone receptor (AR) gene on chromosome X. The 
accumulation of the pathogenic AR proteins in the nucleus of motor neurons is 
central to the pathogenesis of this disease. AR is expressed ubiquitously and non-
neurological symptoms are common in KD. Of note, nuclear accumulation of the 
pathogenic AR was observed in autopsied myocardium (117). 
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A population of affected 144 patients from Japan was evaluated to clarify 
myocardial involvement in KD and it was reported an increased incidence of 
Brugada-type ECG changes. Among ECG abnormalities, a Brugada type ECG was 
detected in 17 patients (11.8%) and particularly type 1 was found in 6 subjects, type 
2 in 7 subjects, and type 3 in 4 subjects. Moreover, 2 subjects had symptomatic BS 
and both of them experienced SCD. Genetic test was performed but no gene 
mutation associated with BS was found. Interesting, a marked decrease in 
messenger RNA levels of SCN5A was demonstrated in these 17 affected patients. 
 
ICD implantation: efficacy and safety 
 
ICD is the only proved life-saving treatment for patients with cardiomyopathies and 
channelopathies at high risk for SCD; nevertheless, it is not free from complications 
and it might lead to a significant morbidity and reduced quality of life, particularly in 
young patients (118). There is a strong agreement for ICD implantation in secondary 
prevention, i.e. in patients who survived a cardiac arrest (29, 41, 57, 93-95); whether 
to implant or not an ICD in patients with an arrhythmogenic cardiomyopathies and 
no previous history of aborted SCD is still a matter of debate. Risk stratification is 
challenging in young people with cardiac diseases at risk for SCD, because it allowed 
the identification of patients with a high probability of a malignant arrhythmic 
outcome that are eligible for ICD implantation.  
ICD efficacy is primary due to its ability in terminating VF and VT with delivery of 
antitachycardia overdrive pacing (ATP) or shock. VF always bring to sudden death if 
not interrupted; on the contrary, VT could also be hemodynamic well tolerated and 
could terminate spontaneously or with pharmacological therapy, not necessarily 
leading to fatal VF. ICD interventions against VF are always lives saving, while ICD 
interventions against VT, although appropriate, are not. 
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ICD-related morbidity is mainly due to device related complications at the time of 
implant or during follow-up and to inappropriate ICD interventions (118). 
Complications during ICD implantation procedure include pneumothorax, pocket 
haematoma, ventricular lead perforation with or without haemopericardium, 
catheter dislodgment and thromboembolic events (118). 
Complications that may occur during follow-up are pocket haematoma, non septic 
pocket decubitus (Figure 10), device infection, lead dislodgement, cardiac lead 
perforation, lead failure/lead fracture and generator malfunction. 
 
 
Figure 10. Pocket decubitus with skin erosion and exposure of the device. 
 
Some of these adverse events could be treated with medical therapy, but in most 
cases they need a surgical revision of the system. In the study from Olde Nordkamp 
et al lead failure was the most frequent ICD-related complications (119); the 
treatment consisted in a surgical intervention for lead extraction and a repositioning 
of a new system (Figure 11). Lead failure can be completely asymptomatic and 
detected during routine device control as variation of more than 50% of pacing 
threshold or catheter impedance respects the normal patient value; in some cases it 
manifest as a inappropriate ICD interventions due to oversensing. Also lead 
dislodgment or cardiac lead perforation may present with inappropriate ICD 
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interventions or may be asymptomatic; cardiac lead perforation may also be 
associated with hemopericardium with cardiac tamponade, a serious and 
sometimes fatal event. In both cases lead repositioning is necessary. 
 
 
Figure 11. Ventricular ICD lead after extraction with evidence of fibrosis. 
 
Pocket hematoma can be managed conservatively but in some cases pocket revision 
is necessary to find the bleeding source. 
Pocket decubitus and device infection could be very dangerous and are correlated 
with long hospital stay; in both cases extraction of all the system is needed and the 
repositioning of a new device is possible only after antibiotic therapy when no more 
sign of active infection is present (118). 
Inappropriate ICD intervention is defined as an ICD shock delivered not in response 
to VF or VT. The most frequent causes are 1) supraventricular arrhythmias such as 
sinus tachycardia or atrial fibrillation, 2) oversensing both of cardiac signals and of 
extra cardiac signals like myopotentials, 3) lead failure. In young patients the type of 
trigger of the inappropriate intervention depends on the life style and the 
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underlying pathology; in HCM and in LQTS oversensing of the T wave is one of the 
most frequent cause of inappropriate shock. In active patients, sinus tachycardia 
and oversensing of myopotential are also important trigger. The management of 
this complication consist first in device reprogramming (118). In the MADIT-RIT trial 
conducted in patients with ICD for primary prevention because of ischemic disease 
or DCM, different types of ICD programming were tested. This study demonstrated 
that a high minimum threshold for therapy and long detection time were associated 
with a reduce incidence of inappropriate ICD interventions (120). 
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AIMS OF THE STUDIES 
 
BS is a leading cause of SCD in young people. Molecular genetic has provided new 
insights in understanding the pathophysiology of the disease, but its real course is 
still unpredictable and risk stratification is challenging for this patients.  The only 
therapy providing life-saving protection by effectively terminating life-threatening 
arrhythmic episodes is ICD. However young individuals with an inherited arrhythmic 
cardiomyopathy like BS are likely to survive for many decades, living a normal life 
and some even practice competitive sports activity; this condition increases the risk 
of inappropriate shocks and lead-related complications, which might lead to 
morbidity and reduce the quality. 
The research project included three different studies that were performed during 
the four years of the PhD program. 
The purpose of our first study was to assess the prognostic value of clinical and 
electrocardiographic parameters in patients with a Brugada-like ECG pattern (either 
spontaneous or drug-induced type-1). We expected to get new insights about risk 
stratification in BS, using a non-invasive simple exam such as ECG. 
The purpose of our second study was to evaluate the balance between the efficacy 
of ICD in preventing SCD and the risk of ICD-related complications in young 
individuals (18-35 year-old) with different structural cardiomyopathies and primary 
electrical heart diseases (including BS), during a long-term follow-up. 
The third study focused on the prevalence of a Brugada ECG pattern in patients with 
KD. Although an overt cardiomyopathy has not been identified in KD, an increased 
incidence of Brugada-type ECG changes was previously reported in a large affected 
population from Japan (where the prevalence of Brugada ECG pattern is high) (117). 
The aim of our third study, which was carried out in collaboration with the 
Department of Neurosciences of the University of Padova, was to determine the 
prevalence of the Brugada ECG pattern in a large Italian cohort of patients with KD. 
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METHODS 
 
First study: prognostic value of ECG abnormalities in Brugada Syndrome 
 
Study population 
We conducted a multicentre prospective study from 1995 to 2015 in 3 medical 
centres of the Veneto Region of Italy (the University Hospital of Padova, the General 
Hospital of Conegliano and the General Hospital of Mestre). We enrolled 272 
consecutive patients presenting with a spontaneous or drug-induced type 1 Brugada 
ECG pattern (coved-type), according to the Brugada diagnostic criteria available at 
the time of the diagnosis (56, 62, 64). 
For each patient we collected the following data: age at the diagnosis, sex, physical 
examination, personal and family medical history, baseline ECG, provocative test 
results and echocardiography. The family history was obtained at the first clinical 
evaluation and was considered positive if at least 1 first-degree family member 
showed type 1 Brugada ECG pattern or died suddenly before the age of 40 year-old 
in males and 50 year-old in females in the absence of known heart disease. Syncope 
was defined as a non-traumatic and transient loss of consciousness. Other 
important clinical variables collected in this study include the history of cardiac 
arrest/aborted sudden death and of atrial fibrillation. 
Some patients underwent electrophysiology study (EPS) and other ICD implantation, 
according to the best clinical practice and to the current available guidelines. 
Patients with structural cardiac abnormalities, on-going ischemia, metabolic or 
electrolytic disorders mimicking ECG Brugada pattern were not enrolled in this 
study. The study was approved by the institutional review board and was conducted 
in compliance with the principles of outlined in the Declaration of Helsinki. All 
patients gave their informed consent. 
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Electrocardiographic analysis 
For every patient a 12 lead ECG were recorded at the time of the diagnosis, when no 
antiarrhythmic drug therapy was assumed. Three experienced electrophysiologists 
blinded to patients and clinical presentation evaluated all ECGs (F.M.; M.S.; M.T.). In 
case of disagreement, a fourth cardiologist was consulted. The ECGs were recorded 
at 25 mm/s of paper speed, 1 mV/10 mm gain and 0.05-150 Hz filter. 
Type 1 (coved-type) ECG was defined as a prominent coved ST-segment elevation 
displaying J wave amplitude or ST-segment elevation ш 2 mm (0.2 mV) followed by a 
negative T wave with little or no isoelectric separation in the right precordial leads 
(V1-V3) positioned in the 2nd, 3rd or 4th intercostal space. Type 2 (saddleback-type) 
ECG has a J poiŶt eleǀatioŶ ш 2 mm, followed by ST-segment elevation ш 1 mm above 
the baseline, followed by a positive or biphasic T-wave. Type 3 has either a 
saddleback or coved appearance with an ST-segment elevation of <1 mm. The 
maximal ST-segment elevation was measured at the J point (STJ) in leads V1 to V3. 
The following basal ECG characteristics were analysed: heart rate, PQ, QRS and QT 
intervals, the presence of conduction disturbances, the amplitude and duration of S 
wave in the lead I, II or III, and the presence of an early repolarization pattern in 
infero-lateral leads and of QRS fragmentation in leads V1 to V3.  
The heart rate, the PQ interval and the QRS and corrected QT duration were 
measured in lead II and V6. A PQ interval > 200 ms and a QRS interval > 120 ms were 
considered pathological (121). The QT interval was corrected for rate by the 
Bazette͛s forŵula. Right bundle branch block, left bundle branch block, left anterior 
fascicular block, and left posterior fascicular block were defined in accordance with 
current guidelines (121). The presence of an S-ǁaǀe ш Ϭ.ϭ ŵV aŶd/or > ϰϬ ŵs iŶ 
leads I, II, and III was examined as described previously (105). Early repolarization 
pattern was defined as an elevation of the J-point of at least 1 mm above the 
baseline level in at least 2 consecutive leads, either as QRS interval slurring or 
notching in the inferior (II, III, aVF) or lateral (I, aVL, and V4 to V6) leads (70, 109, 
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110). Fragmented QRS was defined as the presence of 2 or more spikes within the 
QRS complex, as described previously (98). 
 
Provocative test, electrophysiological study and ICD implantation 
All patients where treated according to the current guidelines and to the best 
clinical practice. 
Provocative test with ajmaline (1 mg/kg in 5-10 minutes) or flecainiede (2 mg/kg in 5 
minutes) was performed in patients presenting with a spontaneous type 2 or 3 
Brugada ECG pattern during continuous 12-lead ECG and blood pressure monitoring. 
The test was considered positive if a type 2 or type 3 ECG converted to type 1 after 
the administration of the drug, either in conventional leads V1 to V3 or at leads V1 
and V2 positioned over the third intercostal space (11, 56, 70). 
EPS was performed with risk stratification purpose in accordance with the current 
available guidelines (56, 62, 64).  However, in all cases, the protocol included 
baseline AH and HV intervals and ventricular premature stimulation at the apex and 
outflow tract of the right ventricle at 2 drive cycle lengths (600 and 400 ms) 
delivering up to 3 ventricular extrastimuli with minimum coupling interval of 200 ms 
(56). The test was considered positive if a sustained VF or VT lasting for >30 seconds 
or requiring termination because of hemodynamic compromise was induced. 
Inducibility at PVS was deemed a proper indication for ICD implantation (56).  
High-risk patients with a previous history of cardiac arrest/aborted sudden death 
underwent directly ICD implantation for secondary prevention. 
 
Follow up  
Patients underwent serial outpatient visits or telephonic interviews to determine 
whether they experienced any adverse event during follow-up. The primary 
outcome of the study was the index combined endpoint of major arrhythmic events 
which included SCD, cardiac arrest due to VF and appropriate ICD intervention. SCD 
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was defined as any natural death occurring instantaneously or within 60 minutes 
from symptoms onset. Appropriate ICD intervention was defined as an ICD 
discharge delivered in response to a ventricular tachyarrhythmia and documented 
by stored intracardiac ECG data.  
 
Statistical analysis 
Categorical differences between groups were evaluated by using the X2 test or the 
Fisher exact test, as appropriate. Continuous variables were expressed as mean ± 
standard deviation or median with 25 to 75 percentiles for normally distributed and 
skewed variables, respectively and compared with Student t test or Wilcoxon rank 
sum test, as appropriate. Normal distribution of continuous variables was assessed 
using the Kolmogorov-Smirnov test. The mean event rate per year was evaluated by 
the number of events occurring during the follow-up divided by the number of 
patients multiplied by the average duration of follow-up. Event-free survival curves 
were drawn with the Kaplan-Meier method and compared by using the logrank test. 
Patients were censored at the time of their first event or at the time of their last 
clinical follow-up. Variables with a p-value <0.15 at univariate analysis were also 
entered into the multivariate model. A 2-tailed P<0.05 was considered statistically 
significant. All analyses were performed using SPSS 18 (SPSS Inc; Chicago, IL). 
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Second study: risk-benefit ratio of implantable cardioverter defibrillator (ICD) in 
young patients with cardiomyopathies and channelopathies 
 
Study population 
The study population included 96 consecutive patients with structural 
cardiomyopathies or primary electrical disorders (channelopathies) referred to our 
Department for ICD implantation between January 1997 and December 2013, who 
were 18-35 year-old at the time of the procedure. Baseline clinical (including age, 
sex, body mass index (BMI), type of underlying cardiomyopathy, clinical history) and 
ICD related data including type of ICD (i.e. single or dual-chamber) and type of lead 
(i.e. single or dual coil and active or passive fixation) at the time of implantation 
were collected. BMI was calculated as weight in kilograms divided by height in 
meters squared. Patients were considered underweight if the BMI was less than the 
5%0 in patients younger than 20 years old and less than 18.5 in those 20 years old or 
older (122). The institutional review board approved the study and all patients gave 
their informed consent. 
 
ICD implantation 
Experienced electrophysiologists performed all implantation procedures via the left 
subclavian vein in the subcutaneous pectoral region. Electrical parameters, 
including, sensing, impedance and pacing threshold were recorded at the end of the 
implant. A routine chest radiography and echocardiography were performed the day 
after the procedure to rule out complications. All devices were capable of ATP, 
antibradycardia pacing, delivering shock therapy and were able to record and store 
intracardiac electrograms before and after the therapy was delivered, thus allowing 
for correct classification of the treated arrhythmia. The rate cut-off for detection of 
VF or VT and activation of ATP was set at the discretion of managing 
electrophysiologist to avoid inappropriate ICD intervention and to guarantee 
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successful therapy of ventricular tachyarrhythmias. Secondary prevention was 
defined as ICD implant after resuscitated cardiac arrest or documented sustained 
VT/VF. The absence of a secondary prevention indication defined a primary 
prevention. 
 
Follow-up  
The follow-up started 24 hours after ICD implantation and data were obtained 
prospectively during regular outpatient visits at 1 month after implant and then at 3 
to 6 months intervals. Routine ICD interrogation and ECG recording at the time of 
symptoms were used to document the occurrence of spontaneous VT during follow-
up. At each scheduled or unscheduled visit, the pocket was assessed, the device 
storage was checked for delivered therapy (appropriate/inappropriate), and the 
integrity and appropriate functioning of the pacing system were proved. The study 
end points were cardiac mortality, appropriate ICD intervention, inappropriate ICD 
intervention and device-related complications. Adverse ICD-related events were 
defined as the occurrence of either an inappropriate ICD intervention or a device-
related complication requiring surgical revision occurring more than 24h after 
implantation. Complications occurring within 24h after the procedure (i.e. 
pneumothorax, hemothorax and acute cardiac perforation) were excluded from the 
analysis.  
 
Definitions of events 
Cardiac mortality was defined as SCD, death from end-stage heart failure, and heart 
transplantation. Patients undergoing heart transplantation were censored at the 
time of the procedure. Appropriate ICD interventions were defined as a device 
shock or ATP delivered in response to a sustained ventricular tachyarrhythmia and 
documented by stored intracardiac ECG data. VF or ventricular flutter were defined 
as irregular or regular tachycardia with regard to polarity, amplitude, morphology, 
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and sequence of intracardiac electrograms, with a cycle length of 240 ms or less. VT 
was defined as regular tachycardia with a mean cycle length longer than 240 ms. 
Intervention was considered inappropriate when triggered by heart rates exceeding 
the programmed threshold, as a consequence of sinus tachycardia, supraventricular 
arrhythmias, or device or lead malfunction. All stored electrograms of arrhythmic 
events that triggered ICD therapy were classified as appropriate or inappropriate 
independently by 2 experienced electrophysiologists (F.M.; D.C.). In case of 
disagreement, a third electrophysiologist was consulted.  
Device-related complications requiring surgical revision included: cardiac lead 
perforation, pocket haematoma, non-septic pocket decubitus, device infection, lead 
dislodgement, lead failure/lead fracture, and generator malfunction. For the 
purpose of this study we considered only atrial and ventricular lead perforation 
occurring more than 24h after implant (excluding lead perforation at the time of 
procedure), suspected by chest x-ray and confirmed by computed tomography 
(123). Pocket hematoma was defined as a palpable mass that protruded more than 
2cm anterior to the device. The criteria for the surgical drainage of pocket 
hematoma included progressive enlargement not expected to resolve with 
conservative treatment, the presence of tense swelling causing poor capillary 
perfusion and haematoma causing severe pain. Non-septic pocket decubitus was 
defined as the thinning of the skin above the generator with signs of local 
inflammation, such as erythema, warmth, fluctuance due to mechanical decubitus 
without skin perforation or evidence of device infection. Device infection was 
defined by the presence of local signs of inflammation including skin 
erosion/perforation, wound dehiscence or purulent drainage with bacterial growth 
wound cultures or lead vegetations detected by echocardiography or the fulfilment 
of modified Duke criteria for infective endocarditis (124, 125). Lead dislodgement 
was defined as inadequate capture and/or sensing or phrenic nerve stimulation with 
(macrodislocation) or without (microdislocation) a visible change in the lead position 
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on chest X-ray, irresolvable by device reprogramming. Lead failure, including lead 
fracture, was defined as a non-physiologiĐal ĐhaŶge ;шϱϬ% as Đoŵpared ǁith 
chronic values) in the impedance with change in the sensing/pacing threshold 
(intermittent or permanent) and/or electrical noise artefacts from rapid, 
nonphysiological make-break potentials recorded on the sensing channel with or 
without visible lead fracture on chest radiography and without evidence of lead 
dislodgement (126, 127). Oversensing of non-cardiac potentials, such as 
electromagnetic interferences, were not considered lead failure for the purpose of 
this analysis. Generator malfunction was defined as any malfunction of the pulse 
generator requiring premature replacement. 
 
Statistical analysis 
Results are summarized as mean ± standard deviation or median with 25 to 75 
percentiles for normally distributed and skewed variables, respectively. Normal 
distribution was assessed using Shapiro–Wilk test. Kaplan–Meier analysis was used 
to estimate the survival distributions of the end points. Start of follow-up was 
defined as the date of the ICD implantation. Patients were censored at the time of 
their first event or the time of their last clinical follow-up. The mean event rate per 
year was evaluated by the number of events occurring during the follow-up divided 
by the number of patients multiplied by the average duration of follow-up. 
Univariate analysis was used to determine predictors of inappropriate ICD 
interventions and both univariate and multivariate Cox regression analysis were 
used to determine predictors of device-related complications. Because of the 
heterogeneity of the underlying cardiac diseases, the analysis for predictors of 
appropriate events was not performed. Variables with a probability value <0.15 
were integrated into multivariable analysis using Cox proportional-hazard models to 
estimate the Hazard ratio (HR) and to identify independent predictors of outcome. A 
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value of P<0.05 was considered significant. Statistics were analyzed with SPSS 
version 17 (SPSS Inc, Chicago, IL). 
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Third study: prevalence of Brugada syndrome in Kennedy’s Disease 
 
In our third study, 73 consecutive Italian patients with KD underwent a full clinical 
protocol including biochemical and hormonal analyses, genitourinary examination, 
bone metabolism and densitometry, cardiological evaluation and muscle pathology. 
Cardiological evaluation included clinical history, standard 12-lead ECG and standard 
two-dimensional Doppler echocardiography. Additionally, all patients underwent a 
modified ECG recording with right precordial leads placed to the third and second 
intercostal spaces, to increase the sensitivity for Brugada-like abnormalities. 
Brugada-like ST-segment and T-wave (ST-T) abnormalities in right precordial leads 
were classified according to the second consensus conferences on the Brugada 
syndrome (62). The sodium channel blocker test was not performed. All ECGs were 
evaluated by two experienced electrophysiologists (D.C. and M.S.). 
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RESULTS 
 
First study: prognostic value of ECG abnormalities in Brugada Syndrome 
 
Patients’ characteristics 
The study population consisted of 272 consecutive subjects (223 men; mean age 
43±12 years), whose baseline clinical characteristics are shown in Table 3. At 
enrolment, 81 patients (30%) were symptomatic for arrhythmic syncope (73; 26%) 
or had history of cardiac arrest (8; 3%); 124 (45%) had a family history of BS or SCD 
and 19 patients (7%) had a history of paroxysmal atrial fibrillation. A spontaneous 
type 1 ECG pattern was observed in 137 patients (50%). 143 patients (52,5%) 
underwent EPS, and 51/143 (35%) were inducible to sustained VT or VF. 69 patients 
(25%) received a prophylactic ICD because of cardiac arrest (n=7), syncope (n=38), or 
inducibility at PVS in the absence of symptoms (n=24).  
 
Electrocardiographic findings  
ECG findings of the study population are reported in Table 3. Half of our population 
presented with a spontaneous type 1 ECG. Mean QRS duration was 105±25 ms in 
lead II and 109±15 ms in lead V2. The mean QTc interval was 402±33 ms. Left 
anterior fascicular block was present in 48 patients (18%), 5 patients (2%) presented 
a f-QRS in leads V1, V2, and V3. A first-degree AV block was present in 45 patients 
;ϭϲ.ϱ%Ϳ; of these, Ϯϳ uŶderǁeŶt EP“ aŶd aŶ HV iŶterǀal шϱϱ ŵseĐ ǁas recorded in 
21 (78%). A first-degree AV block was significantly more frequent in patients with 
spontaneous versus drug-induced type 1 ECG (P = 0.009) (Table 4). An infero-lateral 
ER pattern was observed in 9 patients (3%).   
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Table 3. Baseline clinical and electrocardiographic characteristics of the study population. 
 
Clinical and ECG characteristics 
Population 
N = 272 (%) 
Age (yr; mean  SD) 4312 
Male Gender  223 (82) 
Family history  
  Family history of BS 51 (19) 
  Family history of SCD 73 (27) 
Personal history  
  History of syncope 73 (26) 
  History of CA 8 (3) 
  History of syncope or CA 81 (30) 
  History of palpitations 51(19) 
  History of atrial fibrillation 19 (7) 
Inducibile VT/VF at EPS 51/143 (35) 
ICD recipients 69 (25) 
ECG  
  First degree AV block 45 (16,5) 
  Spontaneous type 1 137 (50) 
  QRS duration in D2 (ms; mean  SD) 10525 
  QRS duration in V2 (ms; mean  SD) 10915 
  QTc interval (ms; mean  SD) 40233 
  Fragmented QRS 5 (2) 
  Left anterior fascicular block 48 (18) 
  Early repolarization 9 (3) 
  S-wave in lead I 134 (49) 
  S-wave in lead II 181 (66) 
  S-wave in lead III 
  S1S2S3 pattern 
157 (58) 
71 (26) 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 
standard deviation. SD=standard deviation; BS=Brugada Syndrome; SCD=sudden cardiac death; CA=cardiac arrest; 
VT=Ventricular Tachycardia; VF=Ventricular fibrillation; EPS=electrophysiological Study; AV= atrio-ventricular. 
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Table 4. Baseline clinical and electrocardiographic characteristics of patients with and without 
first-degree AV block. 
 
 Presence of 
first-degree AV Block 
n = 45 (%) 
Absence of 
first-degree AV Block 
n = 227(%) 
p 
Age (yr) 47 (32-58) 43 (33-51) 0.27 
Male Gender 37 (82) 186 (82) 1.0 
Family history    
 Family history of BS 13 (29) 38 (17) 0.063 
 Family history of SCD 17 (38) 56 (25) 0.096 
Personal history    
 History of syncope 11 (24) 62 (27) 0.85 
 History of CA 1 (2) 7 (3) 1.0 
 History of syncope or CA 11 (24) 70 (30) 0.33 
 History of palpitations 8 (18) 43 (19) 1.0 
 History of AF 0 (0) 2 (1) 1.0 
Inducibile VT/VF at EPS 13 (48) 38 (33) 0.18 
ECG    
 Spontaneous type 1 31 (67) 106 (47) 0.009 
 QRS duration in D2 (ms) 110 (100-120) 95 (80-120) 0.042 
 Left anterior hemiblock 13 (29) 35 (16) 0.056 
Fragmented QRS  0 (0) 4 (2) 1.0 
 Early repolarization 2 (4) 7 (3) 0.64 
 S-wave in lead I 27 (61) 107 (47) 0.10 
 S-wave in lead II 31 (70) 150 (66) 0.72 
 S-wave in lead III 25 (57) 132 (59) 0.86 
 S1S2S3 pattern 13 (29) 58 (26) 0.71 
 QTc (ms) 400 (377-421) 400 (380-420) 0.854 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 25% 
and 75%, respectively. AF = atrial fibrillation; AV = atrioventricular; BS = Brugada syndrome; CA = cardiac arrest; 
EPS=electrophysiological study; SCD = sudden cardiac arrest; VT/VF = ventricular tachycardia/ventricular fibrillation. 
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Follow-up 
The mean follow-up period for the entire study population was 85±44 months. 
Seventeen patients (6.3%) experienced at least 1 arrhythmic event (annual 
incidence rate =0.9%), which consisted of SCD in 4 (1.4%) and appropriate ICD 
interventions on VF in 13 (5%). Six patients (8.7%) experienced device-related 
complications including lead failure (n=2), lead dislocations (n=1) and infections 
(n=3) requiring surgical revision. Compared with patients with an uneventful 
outcome, those who experienced arrhythmic events during follow-up had 
significantly more often a history of CA or syncope (P < 0.001) and were more likely 
inducible at EPS (P = 0.004) (Table 5). There was no significant difference between 
patients who did and did not have arrhythmic events during follow-up with regard 
to age, gender, history of palpitations or atrial fibrillation and family history for BS or 
SCD. Among the ECG parameters, a spontaneous type 1 ECG pattern (P =0.01) and a 
first-degree AV block at baseline (P <0.001) were significantly more often observed 
in patients with arrhythmic events (Table 5). No others ECG depolarization or 
repolarization abnormalities differed between the two groups (Table 5).  
 
Predictors of Events 
Kaplan-Meier analysis for event-free survival according to first-degree AV block is 
shown in Figure 12. Univariate and multivariate analysis for predictors of any 
arrhythmic events during follow-up are shown in Table 6. Univariate predictors of 
events included a previous history of cardiac arrest or syncope, a spontaneous type 
1 ECG pattern and the presence of a first-degree AV block at baseline ECG. In a 
multivariate model these parameters remained significant predictors of an 
arrhythmic outcome (P<0.001, P = 0.04 and P = 0.002, respectively). 
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Table 5. Clinical characteristics of patients with and without major arrhythmic event during follow-
up. 
 
 
No event 
N=255 
Event 
N=17 
p 
Age (yr) 43 (33-53) 44 (31-50) 0.60 
Male gender 207 (81) 16 (94) 0.32 
Family history    
 Family history of BS 46 (18) 5 (29) 0.25 
 Family history of SCD 66 (26) 7 (41) 0.17 
Personal history    
 History of syncope 63 (25) 10 (59) 0.002 
 History of CA 4 (2) 4 (24) 0.001 
 History of syncope or CA 69 (27) 12 (71) <0.001 
 History of palpitations 48 (19) 3 (18) 1.0 
 History of AF  17 (7) 2 (12) 0.34 
Inducible VT/VF at EPS 43/133 (32) 8/10 (80) 0.004 
ECG    
 First degree AV block 37 (15) 8 (47) <0.001 
 Spontaneous type 1 126 (49) 12 (71) 0.01 
 QRS duration in D2 (ms) 100 (80-120) 120 (100-120) 0.06 
 QRS duration in V2 (ms) 100 (100-120) 120 (100-135) 0.06 
 Fragmented QRS 4 (2) 1 (6) 0.29 
 Left anterior hemiblock 45 (18) 3 (18) 1.0 
 Early repolarization 7 (3) 2 (12) 0.10 
 S-wave in D1 124 (49) 10 (59) 0.43 
 S-wave in D2 169 (67) 12 (71) 0.75 
 S-wave in D3 144 (57) 13 (77) 0.14 
 S1S2S3 pattern 62 (26) 7 (44) 0.11 
 QTC (ms) 400 (380-420) 413 (387-428) 0.35 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 25% 
and 75%, respectively. AV = atrioventricular; BS = Brugada syndrome; CA = cardiac arrest; EPS = electrophysiological 
study; SCD = sudden cardiac arrest; VT/VF = ventricular tachycardia/ventricular fibrillation. 
 
 69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Kaplan-Meier analysis for event-free survival according to first-degree AV block 
(AVB=atrio-ventricular block). 
 
Table 6. Univariate and multivariable predictors of major arrhythmic event during follow-up. 
 
 Univariate analysis Multivariate analysis 
 HR 95% CI p HR 95% CI p 
Family history of BS 1.79 0.63-5.09 0.28    
Family history of SCD 1.87 0.71-4.93 0.20    
History of syncope/CA 5.80 2.04-16.5 0.001 6.68 2.34-19.1 <0.001 
Type 1 ECG pattern 1.56 0.57-4.24 0.04 1.84 1.03-4.29 0.04 
First degree AV block 3.84 1.47-9.99 0.006 4.65 2.34-19.1 0.002 
AV = atrioventricular; BS = Brugada syndrome; CA = cardiac arrest; SCD = sudden cardiac arrest. 
 
 
 no AVB 
AVB 
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Second study: risk-benefit ratio of implantable cardioverter defibrillator (ICD) in 
young patients with cardiomyopathies and channelopathies 
 
Patient and ICD Characteristics 
The study population included 96 consecutive patients [68 men; median age 27 
years (22-32)]. Baseline clinical characteristics of the overall study population and 
according to the underlying cardiomyopathy are summarized in Figure 13 and Table 
7. Underlying disease substrate included structural cardiomyopathy in 71 patients 
(74%), such as ARVC (n=35), DCM (n=17), HCM (n=15) and LVNC (n=4); and primary 
electrical disorders in 25 patients (26%), including BS (n=14), IVF (n=5), LQTS (n=4) 
and SQTS (n=2). Sixty-nine patients (71.9%) received an ICD implantation for primary 
prevention and 27 (28.1%) for secondary prevention. A single-chamber ICD was 
implanted in 83 (86.5%) patients, whereas a dual-chamber ICD was implanted in 13 
(13.5%). Of the 96 ventricular leads, 58 (60.4%) had an active and 38 (39.6%) a 
passive fixation mechanism; 32 (33.3%) leads had a single coil and 64 (66.6%) a dual 
coil. Three patients received a Medtronic Sprint Fidelis (Medtronic, Inc., 
Minneapolis, Minnesota, USA) lead, which was subsequently withdrawn from 
trading while none received St. Jude Riata (St Jude Medical, Sylmar, California, USA) 
lead. In 55 (57.3%) patients, only one therapy zone was programmed and in the 
remaining patients two therapy zones. The minimal median threshold for 
intervention was 300 ms (300-273 ms). ATP with multiple bursts in the ventricular 
tachycardia zone was activated in the 41 patients with more than one therapy zone. 
In 31 patients with a single-therapy zone who received an ICD that supported this 
function, before/during charge ATP was also programmed. In 24 patients who 
initially received an older device with no programmable ATP in the ventricular 
fibrillation zone, this therapy was activated at the time of ICD replacement. 
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Table 7. Clinical characteristics of overall sample and according to the underlying 
cardiomyopathy/channelopathies. 
 
* Only for patients affected by ARVC, DCM, HCM and LVNC; ** Only for patients affected by HCM. 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 25% 
and 75%, respectively. ARVC=arrhythmogenic right ventricular cardiomyopathy; DCM=dilatative cardiomyopathy; 
HCM=hypertrophic cardiomyopathy; LVNC=left ventricular non compaction; BS=Brugada Syndrome; LQTS=Long QT 
Syndrome; SQTS=Short QT Syndrome; IVF=idiopathic ventricular fibrillation; BMI=body mass index; SCD=sudden 
cardiac death NSVT=non sustained ventricular tachycardia; PVS=programmed ventricular stimulation; LVEF=left 
ventricular ejection fraction; SVT= sustained ventricular tachycardia. 
 
Outcome 
During a mean follow-up of 72.6 ± 53.3 months, 20 (20.8%) patients had a total of 
38 appropriate ICD interventions and 26 (27.1%) experienced a total of 49 adverse 
 
Overall 
sample 
96 (%) 
ARVC 
35 
(36.5%) 
DCM 
17 
(17.5%) 
HCM 
15 
(15.6%) 
LVNC 
4     
(4.2%) 
BS 
14 
(14.6%) 
LQTS 
4    
(4.2%) 
SQTS 
2    
(2.1%) 
IVF 
5    
(5.2%) 
Age (years) 
27 
(22-32) 
27 
(20-33) 
30 
(31-34) 
28 
(22-362 
19 
(21-25) 
26 
(24-31) 
30 
(26-31) 
31 
29 
(26-30) 
Sex (male) 
68 
(70.8) 
25 
(71,4) 
10 
(58,8) 
9 
(60) 
4 
(100) 
14 
(100) 
1 
(25) 
1 
(50) 
4 
(80) 
BMI 
24  
(22-26) 
24  
(23-25) 
25 
(22-27) 
26 
(21-30) 
23 
(20-24) 
24 
(22-25) 
23 
(20-25) 
24 
(21-24) 
24 
(21-25) 
Underweight status 
7 
(7.3) 
2 
(5.7) 
2 
(11.8) 
1 
(6.7) 
1 
(25) 
0 
(0) 
0 
(0) 
0 
(0) 
1 
(20) 
Primary prevention 
Family history of SCD 
Previous syncope 
Previous NSVT 
Inducibility at PVS 
 
LVEF  < 35%* 
Septum шϯϬŵŵ ** 
69 (71.9) 
35 (36.5) 
40 (41.7) 
38 (39.6) 
19/30 
(63.3) 
21 (21.9) 
/ 
24 (68.6) 
10 (28.6) 
13 (37.1) 
14(40%) 
9/15 
(60) 
1 (2.9) 
/ 
15 (88.2) 
8 (47.1) 
1 (5,9) 
8 (47,1) 
0/1 
(0) 
17 (100) 
/ 
14 (93) 
8 (53.3) 
6 (40) 
8 (53,3) 
/ 
 
1 (6.7) 
10 (66.7) 
3 (75) 
1 (25) 
2 (50) 
2 (50) 
1/1 
(100) 
2 (50) 
/ 
10 (71.4) 
4 (28.6) 
9 (64,3) 
2 (14,3) 
7/10 
(70) 
/ 
/ 
1 (25) 
2 (50) 
4 (100) 
1 (25) 
/ 
 
/ 
/ 
2 (100) 
2 (100) 
0 (0) 
0 (0) 
2/2 
(100) 
/ 
/ 
0 (0) 
0 (0) 
5 (100) 
3 (60) 
0/1 
(0) 
/ 
/ 
Secondary prevention 
Previous cardiac arrest 
Previous SVT 
27 (28.1) 
17 (17.7) 
12 (12.5) 
11 (31.4) 
5 (14.3) 
6 (17.1) 
2 (11.8) 
1 (5.9) 
1 (5.9) 
1 (6,7) 
0 (0) 
1 (6.7) 
1 (25) 
1 (25) 
1 (25) 
4 (28,6) 
4 (28.6) 
1 (7.1) 
3 (75) 
2 (50) 
1 (25) 
0 (0) 
0 (0) 
0 (0) 
5 (100) 
4 (80) 
1 (20) 
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ICD-related events. The prevalence and distribution of patients with appropriate ICD 
interventions and adverse ICD-related events in the overall population and 
according to the underlying cardiomyopathy is shown in Figure 13. Thirty-five 
(36.5%) patients underwent at least one ICD replacement. In addition, one patient 
with end-stage HCM died because of acute heart failure and 11 (11.5%) underwent 
heart transplantation because of refractory heart failure.  
 
Figure 13. Prevalence and distribution of appropriate ICD interventions and adverse ICD-related 
events in the overall population and according to the underlying cardiomyopathy. Abbreviations 
as in Table 7. 
 
Kaplan-Meier analysis of survival free from appropriate ICD intervention and 
adverse ICD-related events is shown in Figure 14. 
 
Appropriate ICD interventions 
Clinical characteristics of patients with and without appropriate ICD interventions 
are shown in Table 8. Ten patients had a single appropriate ICD intervention and 10 
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had multiple interventions, including 2 patients with ventricular tachycardia storm. 
Sixteen patients had shocks only, 2 had only ATP interventions and 2 had both type 
of interventions.  
A 
 
B 
 
Figure 14. Kaplan-meier analysis for survival free from adverse ICD-related events (A) and 
appropriate ICD interventions (B). 
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The annual rate of first ICD intervention was 4 %/year and the average time from 
implantation to first appropriate ICD intervention was 31.6±35.3 months. The device 
successfully terminated all arrhythmic events.  
 
Table 8. Characteristics of patients with and without appropriate ICD therapy during follow-up. 
 
 Appropriate ICD 
intervention 
N=20 (20.8%) 
No appropriate 
ICD intervention 
N=76 (79.2%) 
 Age (yrs)  29 (20-33) 26 (22-31) 
 Sex (male) 15 (75) 53 (69.7) 
Underweight status 1 (5) 6 (7.9) 
Primary prevention 11 (55) 58 (76.3) 
Structural cardiomyopathy 14 (70) 57 (75) 
Family history of SCD 7 (35) 28 (36.8) 
Previous syncope 10 (50) 30 (39.5) 
Previous NSVT 9 (45) 29 (38.2) 
Inducibility at PVS (performed in 30 pt) 5/7 (71) 14/23 (61) 
Previous cardiac arrest 6 (30%) 11 (14.5%) 
Previous SVT 5 (25%) 7 (9.2%) 
Antiarrhythmic drug therapy 17 (85) 59 (77.6) 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 25% 
and 75%-iles. Abbreviations as in Table 7. 
 
A subgroup of 9 patients (9.4%) experienced at least one ICD intervention on VF or 
ventricular flutter with an average annual rate of first shocks on VF/ ventricular 
flutter of 1.7 %/y and an average time from implantation to first appropriate ICD 
intervention triggered by VF/ ventricular flutter of 31.5±20.5 months. 
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Adverse ICD-related events 
Among the 49 adverse ICD-related events occurring in 26 patients (27.1%), 23 were 
inappropriate interventions and 26 were device-related complications requiring 
surgical revision. Clinical characteristics of patients with and without adverse ICD-
related events are shown in Table 9. Seventeen patients had at least 1 one device-
related complications, 6 received at least 1 inappropriate ICD interventions and 3 
had both device-related complications and inappropriate ICD interventions. The 
annual rate of first adverse ICD-related event was 5.4%/year and the average time 
from implantation to the first adverse ICD-related adverse event was 34.2 ± 38.9 
months. The annual event rate was 3.9%/year for first device-related complication 
and 1.7%/year for first inappropriate ICD interventions. The survival free of first ICD-
related adverse event did not differ between primary and secondary prevention 
patients and between patients with structural cardiomyopathy and primary 
electrical disorder. 
Reasons for the 23 inappropriate ICD interventions occurring in 9 patients (9.4%) 
were atrial fibrillation (n=2), supraventricular tachycardia (n=5) and lead 
malfunction (n=2), whereas the 26 device-related complications requiring surgical 
intervention occurring in 20 patients (20.8%) included ventricular lead 
failure/fracture (n=9), non-septic pocket decubitus (n=8), pocket infection (n=1), 
pocket haematoma (n=1), cardiac perforation (n=1), ventricular lead dislodgement 
(n=4), and device failure (n=2). Five patients suffered multiple device-related 
complications. Patients with pocket infection and lead failure/fracture underwent 
successful percutaneous mechanical lead extraction in the electrophysiology room 
with surgical backup in the absence of any complications. All these patients required 
a new lead and device replacement during the same procedure or after adequate 
intravenous antibiotic treatment in case of infection. All 4 ventricular lead 
dislodgments had an active fixation mechanism; 2 were successfully repositioned 
percutaneously and 2 were replaced by a new ventricular lead. Non-septic pocket 
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decubitus was treated with local skin excision and pocket replacement without 
device removal. Owing to the recurrence of decubitus, surgical pocket revision was 
repeated twice in one patient.  
 
Table 9. Characteristics of patients with and without adverse ICD-related events. 
 
 Adverse events 
N=26 (27.1%) 
No adverse events 
N=70 (72.9%) 
 Age (yrs)  30 (22-34) 26 (19-30) 
 Sex (male) 19 (73.1) 49 (70) 
Underweight status 3 (11.5) 4 (5.7) 
Primary prevention 18 (69.2) 51 (72.9) 
Structural cardiomyopathy 19 (73.1) 52 (74.3) 
Family history of SCD 8 (30.8) 27 (38.6) 
Previous syncope 8 (30.8) 32 (45.7) 
Previous NSVT 13 (50) 25 (35.7) 
Inducibility at PVS 3/8 (37) 16/22 (72) 
Previous cardiac arrest 4 (15.4) 13 (18.6) 
 Previous SVT 4 (15.4) 7 (10) 
Antiarrhythmic drug therapy 19 (73.1) 57 (81.1) 
Minimal therapy threshold 200 (188-220) 200 (200-220) 
Active fixation 15 (57.7) 43 (61.4) 
Single coil 4 (15.4) 28 (40) 
Single chamber ICD 23 (88.5) 60 (85.7) 
* Only for patients affected by ARVC, DCM, HCM and LVNC  
** Only for patients affected by HCM 
Categorical variables are presented as number of patients (%). Continuous values are expressed as median with 25% 
and 75%-iles.  
Abbreviations as in Table 7.  (HR=heart rate; ICD=implantable cardioverter defibrillator) 
 
The patient with cardiac perforation was transferred to the operating room where 
the lead was removed and a new lead was reimplanted via left subclavian vein in the 
absence of any complications. Three patients who developed device-related 
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complication requiring surgical revision (nonseptic pocket decubitus n=2 and lead 
failure n 1=1) received a subcutaneous ICD (S-ICD) after lead extraction. No patients 
died because of ventricular arrhythmias or device-related complications requiring 
surgical revision. 
 
Predictors of inappropriate events and device-related complications 
Univariate and multivariate analysis for predictors of inappropriate ICD 
interventions and device-related complications requiring surgical revision are listed 
in Tables 10 and 11. At univariate analysis, a threshold for ICD therapy less than 300 
ms was associated with a borderline significant lower probability of inappropriate 
ICD interventions (HR=0.2; 95% CI 0.02-1.2; p=0.07). 
 
Table 10. Predictors of inappropriate ICD interventions during follow-up. 
 
 Univariate analysis 
 HR CI P 
Age (years) 1.06 0.9-1.2 0.233 
Sex (male) 1.45 0.3-7.0 0.641 
Primary prevention 0.50 0.1-1.9 0.299 
Structural cardiomyopathy 1.50 0.3-7.3 0.614 
Single lead ICD 1.47 0.2-11.9 0.718 
Apical position 0.62 0.1-5.1 0.653 
Double coil 2.64 0.3-21.9 0.368 
Active fixation 1.35 0.3-5.7 0.680 
Minimum HR threshold  <300 ms 0.20 0.02-1.2 0.07 
Antiarrhythmic drug therapy 1.33 0.3-6.4 0.723 
HR=heart rate; ICD=implantable cardioverter defibrillator. 
 
At univariate analysis, underweight status and age at the time of implant were 
significantly associated with the risk of device-related complications, whereas at 
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multivariate analysis only underweight status remained significant (HR=5.4, 95% C.I. 
1.5-19.4; p=0.01). 
 
Table 11. Predictors of device-related complications during follow-up. 
 
 Univariate analysis Multivariable analysis 
 HR CI P HR CI P 
Age (years) 1.07 1.0-1.2 0.051 1.08 0.91-1.16 0.32 
Sex (male) 0.66 0.3-1.7 0,374    
Primary prevention 1.99 0.7-6.0 0.219    
Structural cardiomyopathy 1.35 0.5-3.8 0.560    
Underweight status 3.86 1.1-13.4 0.034 5.43 1.5-19.4 0.01 
Single lead ICD 1.83 0.4-7.9 0.417    
Apical position 1.02 0.1-7.9 0.983    
Double coil 1.14 0.3-4.3 0.843    
Active fixation lead 2.63 0.9-7.6 0.072    
Previous cardiac arrest 1.24 0.4-3.7 0,697    
Antiarrhythmic drug therapy 0.87 0.3-2.3 0.770    
ICD=implantable cardioverter defibrillator. 
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Third study: prevalence of Brugada syndrome in Kennedy’s Disease 
 
PatieŶts͛ ages raŶged froŵ Ϯϳ to ϳϴ Ǉears ;mean 57.3 years; standard deviation of 
10.2). The mean disease duration since disease onset, which occurred on average at 
42.26±9.4 years (range 29–64; median=46), was 13.1±6.9 years (range 0–29; 
median=13). Twenty-seven patients had hypertension and three had ischaemic 
heart disease. There was no evidence of specific structural heart muscle disease. 
Three patients (4%) had Brugada-like ECG changes. One patient showed a type 2 
͚saddleďaĐk͛ patterŶ iŶ the staŶdard V1-V2 precordial leads (fourth intercostal 
spaĐeͿ, ǁhiĐh ďeĐaŵe tǇpe ϭ ͚Đoǀed tǇpe͛ iŶ upǁard right preĐordial leads ;third 
intercostal space); in the other two patients, Brugada ECG changes were detected 
only in the right precordial leads placed in the third intercostal space and both were 
non-diagŶostiĐ ͚saddleďaĐk͛ patterŶs (types 2 and 3, respectively). Other ECG 
alterations were identified in 15 (20.5%) patients, mostly consisting of left 
ventricular hypertrophy, pathological Q-waves (4 cases) and intraventricular 
conduction abnormalities (3 cases). 
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DISCUSSION 
 
The two present prospective studies bring new insights in the risk stratification and 
therapy of patients affected by BS and other cardiomyopathies or channelopathies.  
The first study was designed to assess the clinical determinants of arrhythmic 
outcome in patients with an ECG diagnostic for BS (spontaneous or drug induced) 
during a long-term follow-up, with particular reference to evaluation of the 
prognostic value of ECG abnormalities. The mayor study finding was that the 
presence of first-degree AV block on basal ECG was an independent predictor of 
malignant arrhythmic events in addition to a traditionally recognized risk factor, i.e. 
a spoŶtaŶeous ͞Đoǀed-tǇpe͟ ECG pattern.  
The second prospective study was designed to assess the balance between the 
efficacy in preventing SCD and the risk of complications of ICD therapy in young 
individuals with primary cardiomyopathies and channelopathies during a long-term 
follow-up. Our principal result was a considerable high incidence of ICD related 
adverse events (annual rate of first ICD-related adverse event of 5.4%/year); this 
result highlights the need of an accurate evaluation of risk/benefit ratio of ICD 
implantation in this age group of patients.  
Finally, we conducted a third study, analysing 73 ECGs of patients with KD with the 
purpose to confirm or exclude the presence of a Brugada phenotype. We found a 
lower incidence of Brugada ECG pattern than that reported in the Japanese study 
(117) and no patients presented with ventricular arrhythmia or SCD; however, 4% of 
our Italian population with KD had Brugada like ECG-changes. Our results revealed 
the need for an accurate and serial ECG evaluation to identify Brugada-like 
abnormalities in patients with KD. 
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Risk stratification in Brugada syndrome 
 
Risk stratification is of great importance in the clinical management of patients with 
BS, because it allows the identification of patients with a high probability of a 
malignant arrhythmic outcome and eligible for ICD implantation. The low prevalence 
of the disease and the low incidence of arrhythmic fatal events during follow-up 
make risk stratification a clinical challenge, particularly in patients with no history of 
previous cardiac arrest. The present prospective study on a large cohort of BS 
patients from the Veneto region of northeastern Italy found that a history of cardiac 
arrest or syncope was a strong predictor of future arrhythmic events. Furthermore, 
we demonstrated that among ECG parameters, the presence of first-degree AV 
block was an independent and powerful predictor of VF/SCD in patients displaying a 
coved-type ST-segment elevation diagnostic for BS, either spontaneous or drug-
induced. 
 
Clinical variable and risk stratification 
Previous studies demonstrated that cardiac arrest is a strong indication for ICD 
implantation in BS patients because of the high recurrences of malignant arrhythmic 
events during long-term follow-up (93-95, 106, 111). Also syncope is a strong marker 
of high arrhythmic risk, particularly when occurs in the absence of prodromes and 
specific triggering circumstances; different studies found syncope an independent 
predictor of malignant arrhythmic events in patients with BS, underling the need of 
a prophylactic ICD in those cases (93, 95, 97, 106). Our results are in agreement with 
those from the previous studies and underlie the prognostic value of symptoms in 
BS (Table 12); history of syncope and/or cardiac arrest was an independent 
predictor of major arrhythmic events during long-term follow-up. In literature, the 
incidence of major arrhythmic events in patients with history of syncope was lower 
compered with patients presenting after aborted SCD; moreover, the studies from 
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Priori et al. found syncope as an independent predictors od arrhythmic events 
during follow-up only in combination with the presence of a spontaneous type I ECG 
(98, 112). This is probably due to the different pathogenic mechanism underling 
syncopal episodes in BS. Syncope can be the clinical manifestation of a self-
terminating ventricular arrhythmia or can be of vaso-vagal origin; the latter one is a 
benign clinical manifestation and patients presenting with a vaso-vagal syncope 
have usually a good prognosis. This hypothesis may explain the contrasting results of 
Conte et al., where syncope was not a predictor of arrhythmic events during follow-
up (94). All this data shown that in the clinical practice it could be challenging to 
distinguish this two types of mechanisms underling syncope; nevertheless, patients 
with syncopal episodes should be considered as a high-risk group, particularly in 
combination with other markers of increased arrhythmic risk.  
We confirmed the poor prognostic role of family history (93, 95, 97, 106, 113) both 
of BS and of SCD in predicting malignant arrhythmic events during follow-up. This 
probably reflects the complex genetic backgrounds of the BS; the phenotypic 
expression of the disease is probably the results of the effects of multiple gene 
mutations and also environmental factors play an important role.  
 
Electrophysiological study and risk stratification 
Controversial results emerged from different studies about the prognostic role of 
EPS with PVS. The studies from Brugada (Table 12) brothers highlighted the 
prognostic role of inducibility at EPS (94, 99, 113, 114); on the contrary, data from 
other groups were not able to find a significant association between EPS study 
results and the arrhythmic outcome (93, 98, 106, 112).  
In agreement with the latter studies, in our analysis inducibility at PVS is not a 
predictor of events during follow-up. 
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ECG abnormalities and risk stratification 
Previous studies reported the important role of ECG in risk stratification in BS, 
depolarization and repolarization abnormalities being predictors of malignant 
arrhythmic events during follow-up.  
 
Table 12: Clinical and electrophysiological variable associate with an increased risk of mayor 
arrhythmic events during follow-up. 
 
Clinical 
Variable 
No. 
pts Study design Prevention Study endpoint 
Multivariable analysis 
[hazard ratio (95% 
confidence interval), 
P value] 
References 
Cardiac 
Arrest 
176 Single 
center; 
prospective 
P/S Appropriate ICD 
shock 
 
5.13 (2.03 - 12.96); 
p<0.01 
 
Conte 2015 
 246 Single center; 
prospective 
P/S Appropriate ICD 
shock, death 
19.61 (4.12 -  90.91)  
p < 0.001 
 
Tokioka 2014 
 308 Multicentre; 
prospective 
P/S Appropriate ICD 
therapy 
10.15 (4.4 – 23.6) Sacher 2013 
 1029 Multicentre; 
prospective 
P/S SCD, appropriate 
ICD shock, 
sustained VT/VF 
11 (4.8 - 24.3);  
p<0.001 
 
Probst 2010 
Syncope 246 Single center; 
prospective 
P/S Appropriate ICD 
shock, death 
28.57 (6.14 - 142.86)  
p < 0.001 
 
Tokioka 2014 
 308 Multicentre; 
prospective 
P/S  Appropriate ICD 
therapy 
2.5 (1.2 – 5.2) 
 
Sacher 2013 
 320 Multicentre; 
prospective 
P SCD; VT/VF on 
stored ICD 
electrograms 
 Delise 2011 
 1029 Multicentre; 
prospective 
P/S SCD, appropriate 
ICD shock, 
sustained VT/VF 
3.4 (1.6- 7.4);  
p=0.002 
 
Probst 2010 
Syncope and 
spontaneous 
type I ECG 
 
308 Multicentre; 
prospective 
P VF; appropriate 
ICD interventions 
4.20 (1.38 - 12.79)  
p= 0.012 
 
Priori 2012 
Inducibility 
on EPS 
176 Single center; 
prospective 
P/S Appropriate 
shock 
 
3.38 (1.33 - 8.59) 
p = 0.01 
 
Conte 2015 
 547 Single center; 
prospective 
P SCD, VF 5.88 (2.0 – 16.7) 
p = 0.0001 
Brugada 2003 
VRP < 200 ms 
  
308 Multicentre; 
prospective 
P VF; appropriate 
ICD interventions 
HR: 3.91 (95% CI: 1.03 
to 12.79, p ฀ 0.045) 
 
Priori 2012 
Abbreviations: P=primary; S=secondary; SCD=sudden cardiac death; VF=ventricular fibrillation; 
VRP=ventricular refractory period; VT=ventricular tachycardia. 
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Among repolarisation abnormalities, the presence of a spontaneous type I Brugada 
ECG pattern on basal ECG was found in different studies to be one of the strongest 
predictors of a poor arrhythmic outcome (93, 97, 98, 112); our results are in 
agreement with those previous studies, as a spontaneous type I ECG was at the 
multivariate analysis an independent predictors of events. 
Other repolarisation abnormalities, like QT prolongation (107) and early 
repolarisation in the infero-lateral leads (106, 108-110), have been associated with 
arrhythmic events during follow-up, but our data did not confirm this association. 
Depolarization abnormalities are frequently present in the basal ECG of Brugada 
patients; their prognostic role has also been evaluated in different studies but 
remains elusive and none of ECG conduction parameters are currently used in the 
risk stratification algorithms. In a retrospective analysis of 325 ECG of patients with 
BS, Maury et al. doĐuŵeŶted a first degree AV ďloĐk ;P‘шϮϬϬ ŵsͿ iŶ ϯϱ% of Đases 
and found that it was independently associated with either SCD or appropriated ICD 
discharges (101). Another retrospective study showed that a longer PR interval was 
associated with SCD in women (66). Kanda et al. found longer HV intervals and 
broader QRS in patients with BS who were inducible to VF at PVS compared with 
non-inducible patients, although such conduction abnormalities did not predict the 
arrhythmic outcome (115). Finally, a wider QRS complex in the precordial leads was 
found to be a significant and sometimes independent predictor of life-threatening 
ventricular arrhythmias in BS (102, 103). The only depolarization abnormalities 
associated with a malignant arrhythmic outcome in different prospective studies 
were the presence of fragmented QRS at basal ECG (98, 106) and of a S-wave in lead 
I (105). 
The present investigation differs from these prior retrospective analyses with regard 
to the prospective study design. In our large cohort of BS patients from the Veneto 
region of Northeastern Italy, we found that 16.5% of cases showed a first-degree AV 
block on their basal 12-lead ECG. Of interest, first-degree AV block was shown to be 
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the result of an infra-hissian conduction delay in 78% of the subgroup of patients (24 
of 27) who underwent EPS with intracardiac AV conduction time measurements. 
Compared to BS patients with a normal PR interval, those with first-degree AV block 
also showed a wider QRS.  
Our data, confirm and extend the observations of previous retrospective studies on 
the association between conduction disturbances and poor outcome in Brugada 
syndrome by demonstrating that the presence of first degree AV block (PR interval 
шϮϬϬ ŵs) is an independent and powerful predictor of VF/SCD in patients displaying 
a ͞Đoǀed-tǇpe͟ “T-segment elevation diagnostic for Brugada syndrome, either 
spontaneous or drug-induced.  
In our cohort of BS patients, we did not find any significant association between the 
presence of an S wave in lead I or of a fragmented QRS at basal ECG and arrhythmic 
outcome, either by univariate and multivariable model. 
 
Overlapping phenotype of Brugada syndrome and cardiac conduction disease  
BS is an inherited disease caused by mutations in 18 different genes, the SCN5A 
gene being the most commonly involved gene (70). The SCN5A gene encodes the 
predominant α-subunit of the sodium channel protein Nav1.5 and its mutations in 
BS are responsible for a reduction in the fast inward sodium current (Ina). However, 
only 11–28% of total BS probands carry a mutated SCN5A-gene; less frequent 
mutations associated with BS involved genes that influence with different pathways 
the same cardiac sodium current Ina or, alternatively, the basal inward L-type 
calcium current or the transient outward potassium current Ito (70). The sodium 
current Ina plays a crucial role in the development of the depolarising phase 0 of the 
AP, and so it is a mayor determinant of excitability of myocardial cells and of 
impulse conduction velocity through the heart; an impairment of the current 
balance of the AP and of cardiac conduction is expected to occur in a subset of BS 
patients (80). 
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Different mutations in the SCN5A gene account not only for BS but for a variety of 
clinical phenotypes, also Đalled ͞sodium ion-channelopathies͟ (128). SCN5A-
mutations have been associated with BS, long QT syndrome type 3, sick sinus 
syndrome, atrial still stand, progressive cardiac conduction diseases (Lenègre 
disease), and possibly dilated cardiomyopathy (128). Originally these different 
inherited arrhythmic syndromes were considered as separate clinical entities; in 
contrast, recent data suggested that SCN5A-mutation carriers tend to exhibit 
overlapping clinical manifestations of the distinct SCN5A-related syndromes, which 
is defiŶed as ͚“CNϱA oǀerlap sǇŶdroŵe͛. It has been postulated that there is an 
overlap between Lenègre disease and BS. Lenègre disease is associated with a 
genetically defective SCN5A-gene, like BS; it is a progressive disease of the 
specialized conduction tissue characterized by fibrofatty atrophy of the His-Purkinje 
system. Clinical manifestations of progressive cardiac conduction disease are 
characterized by prolongation of PR/HV intervals and widening of QRS complex with 
a bundle branch block, fascicular block or both, which reflect a reduced excitability 
and conduction delay of the His-Purkinje system as a consequence of genetically 
defective cardiac sodium channel (129, 130). 
It has been already demonstrated that the same mutation in the SCN5A gene can 
lead either to BS or to an isolated cardiac conduction defect in the same family; the 
mechanism of this different phenotypic expression of the same genetic defects is 
not well elucidated, although some studies suggested that the existence of 
modifiers genes play an important role. In this regard, data of experimental studies 
suggest that the presence of a prominent Ito may determine whether loss-of-
function mutations resulting in a reduction in Ina will manifest as a BS or a 
conduction disease (70, 128). 
The results of the present and some previous studies confirmed that patients with 
BS might exhibit variable degree of conduction abnormalities such as prolonged 
PR/HV intervals and widening of QRS complex with right bundle branch block 
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morphology (101, 102, 104). This has been recognized since the initial reports on the 
ECG features of Brugada syndrome, when Corrado et al. found a coexistent 
conduction disturbance in 4 of 19 SCD victims with a Brugada-like right precordial ST 
segment elevation (104). Hence, an attractive hypothesis is that these finding can be 
interpreted as expression of variable degree of overlapping phenotypes -BS and 
Lenegre disease- due to a common genetically determined reduction of Ina. 
Moreover, we found that the presence of a conduction disturbance (first degree AV 
block) was an independent predictors of events in patients exhibiting a diagnostic 
Brugada ECG, suggesting a worse arrhythmic outcome in patients presenting with an 
overlapping phenotype. The explanation of the adverse outcome of patients with a 
phenotype that combines features of BS and conduction disease remains 
speculative. A possible hypothesis is that BS and Lenègre conduction disease are 
both manifestations of the spectrum of phenotypes related to INa reduction, and 
may present in isolation or in combination. The coexistence of some degree of AV 
conduction slowing in patients with a diagnostic Brugada ECG may be a reflection of 
a more complex and severe phenotype, which in turn may account for a more 
malignant arrhythmic outĐoŵe ďǇ a ͞dose effeĐt͟ ŵeĐhaŶisŵ.  
 
ICD therapy in young patients with cardiomyopathies and channelopathies 
 
The major findings of our second study were the following: first, ICD therapy 
provided life-saving protection by effectively terminating all life-threatening 
ventricular arrhythmias; second, the annual rate of first appropriate ICD 
intervention was 4%/year, whereas the annual rate of first ICD-related adverse 
event was 5.4%/year, suggesting that the balance between the potential benefit and 
risk of complications of ICD implantation should be taken into particular account in 
this age group; third, underweight status was the only independent predictor of 
 88 
device-related complications requiring surgical intervention, whereas there was a 
borderline significant association between ICD therapy threshold and inappropriate 
ICD interventions; and fourth, lead failure/fracture was the most common 
complication occur- ring in nine (9.4%) patients, highlighting the need for potential 
alternative ICD implantation techniques. 
ICD therapy is increasingly being used in young adults for prevention of SCD in the 
setting of a heterogeneous group of diseases, including structural cardiomyopathies 
and cardiac channelopathies (15, 29, 31, 41, 42, 46, 57, 94, 70). Previous studies, 
largelǇ iŶ adult patieŶts, haǀe uŶiforŵlǇ deŵoŶstrated that ICD therapǇ is a ͚life-
saving͛ strategǇ iŶ patieŶts ǁith iŶherited ĐardiaĐ diseases ǁith prior spoŶtaŶeous 
VT or VF, because of their high incidence of ventricular arrhythmias recurrence (29, 
41, 57, 93-95). In young patients with primary cardiomyopathy and no prior 
spontaneous life-threatening ventricular arrhythmias, prophylactic indications for 
ICD implantation are still a matter of debate because the probability of arrhythmic 
cardiac arrest may not be sufficiently high to justify ICD therapy. Moreover, young 
ICD recipients with inherited cardiac diseases have a higher life expectancy and a 
more active life than the general population of adults with ICD, and this might result 
in a higher burden of device complications, including lead malfunction and 
inappropriate shocks, leading to surgical revision and reduced quality of life (31, 46, 
56, 94, 118, 119, 126). As a result, the risk – benefit ratio of ICD in young 
cardiomyopathy patients should be considered carefully. 
An important finding of our study is that 20.8% of patients experienced at least one 
appropriate intervention, and 9.4% experienced at least one intervention to 
terminate VF/ventricular flutter, an arrhythmia that is likely to be fatal if left 
untreated. However, the incidence of complications, including inappropriate shocks 
and device-related complications, was also high (27.1%). 
According to our findings, inappropriate shocks remain a common problem, 
occurring in 9.4% of patients, a figure that is lower than that reported by other 
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studies focusing on young patients with inherited arrhythmia syndromes (range 14–
28%) (29, 31, 46, 56, 93, 94, 118, 119, 132). This lower incidence compared with 
previous study results may be explained by the different age of patient populations 
and the different ICD characteristics and programming. In the present study, both 
patieŶts͛ ĐharaĐteristiĐs ;suĐh as use of aŶtiarrhǇthŵiĐ drug therapǇͿ aŶd ICD 
characteristics (particularly single-chamber versus dual-chamber ICD) were not 
associated with an increased risk of inappropriate ICD therapies. These findings 
were supported by others (31, 119, 132, 133). Thus, single-chamber ICD appears to 
be the most appropriate option for young high-risk patients with cardiomyopathy, 
given the lower potential for lead complications than is expected with dual-chamber 
devices. Instead, a minimum threshold for intervention higher than 300 ms was a 
borderline significant predictor of inappropriate ICD interventions, supporting 
previous studies demonstrating that high threshold and long detection 
programming are associated with reductions in inappropriate therapy and all-cause 
mortality during a long-term follow-up (120, 134, 135). In our study, only one 
therapy zone was programmed in the majority of patients (57.3%), and the median 
threshold for intervention was 300ms. This programming may contribute to 
reducing the risk of inappropriate interventions. The incidence rate of adverse ICD-
related complications in our prospective study was similar to that reported in other 
investigations (3.3–9.5%/year). Olde Nordkamp et al. in a single-centre retrospective 
study focused on patients with inherited cardiac disease and reported an overall 
incidence rate of any complication of 7.1%/year (119). At variance with this study, 
we focused on post-implantation ICD complications only, excluding from the 
analysis acute complications (i.e. pneumothorax, haemothorax and acute cardiac 
perforation during procedure), and this may explain the lower incidence of ICD 
complications in our study cohort compared with that reported by Olde Nordkamp 
et al. 
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Our study results demonstrated that baseline clinical characteristics such as 
underweight status at the time of implantation, but not ICD lead characteristics, 
were predictors of adverse device-related events. Among all complications, lead 
failure/fracture requiring lead extraction was the most common adverse event. Our 
findings confirm previous studies in both the young and adult ICD populations, 
reporting that the lead systeŵ ĐoŶstitutes the ͚ǁeakest liŶk͛ iŶ the ICD sǇsteŵ aŶd 
may not be designed to remain intact and perform effectively over the long periods 
required for young patients with decades of productive life ahead (119, 126, 127). 
Remote monitoring is now increasingly used for early diagnosis and management of 
device-related complications in patients with ICD (136, 137). 
A reduced ICD lead diameter may be a particularly useful feature in young patients. 
Thus, small-diameter ICD leads, including Sprint Fidelis and Riata leads, have been 
introduced into clinical practice to facilitate the implantation procedure and to 
potentially reduce the likelihood of venous obstruction and tricuspid valve distortion 
(126). However, different reports have demonstrated an increased rate of 
complications with small-diameter leads, raising the question of whether failure of 
ICD leads is a matter of lead size (138). Recently, Janson et al. demonstrated that 
design rather than diameter is the critical issue in ICD lead survival in young patients 
(127). In our study, among patients with leads failure, only one patient was 
implanted with Sprint Fidelis lead and none with Riata lead, highlighting that lead 
failure is a common ICD-related complication in young patients indepen- dently 
from lead characteristics. 
Apart from lead characteristics, classical subclavian vein access as first choice, used 
in all our patients during the study period, may have increased the risk of lead 
failure. IŶ our studǇ, ǁe oďserǀed tǁo Đases of ͚suďĐlaǀiaŶ Đrush sǇŶdroŵe͛, ǁhiĐh is 
a common long-term lead complication following subclavian vein access, suggesting 
that the type of implantation technique is a critical issue to minimize the risk of lead 
fracture (139). In this regard, axillary vein or cephalic access for ICD lead may offer 
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the potential to avoid lead complications usually observed with traditional 
subclavian vein approach (140, 141). These techniques are currently used in all 
patients undergoing ICD implant in our department. 
S-ICD has recently entered into the clinical practice and may represent a valid 
alternative to the traditional transvenous device, especially among patients with 
limited vascular access, increased risk of infection and structurally normal heart with 
no need for pacing (11, 143, 144). The lack of transvenous and intracardiac 
components makes it an attractive choice also for young patients. However, the 
precise clinical role of S-ICD in young patients with cardiomyopathy remains to be 
defined because of the possibility of an increased risk of T-wave oversensing and 
inappropriate shock delivery, especially in patients with hypertrophic or 
arrhythmogenic cardiomyopathy (145, 146). Moreover, the decision whether to 
implant a leadless device needs to be patient specific, balancing potential lead-
related complications with the likelihood of recurrent VT that may be effectively 
pace-terminated. Although no patient died from ICD complications, adverse events 
increase the number of hospitalizations, surgical revisions and clearly constitute a 
source of incremental costs to the healthcare system as well as reducing the quality 
of life. 
Device longevity is also a very important aspect in the clinical practice both for 
patieŶts͛ safetǇ, ďeĐause deǀiĐe replaĐeŵeŶt Đarries a potential risk of serious 
complications including pocket infection, and for healthcare systems, because of the 
high costs of ICD. The impact of extending ICD longevity is particularly important in 
young individuals with preserved left ventricle systolic function, a subset of patients 
with a relatively long survival in whom avoidance of device replacements is 
paramount (147, 148). 
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Kennedy’s Disease 
 
In our analysis, there was no sign of a structural cardiomyopathy in our patients, as 
previously described (149). A recent study reported a high prevalence (11.8%) of 
Brugada-like ECG in a Japanese population with KD, ascribed to a down regulation of 
the SCN5A gene leading to sodium current reduction in the myocardium (117). Of 
note, two patients had symptomatic Brugada syndrome and died suddenly during 
follow-up. In our study, we found non-diagnostic Brugada ECG abnormalities in 
three patients (4%), mostly recorded in non-conventional upward right precordial 
leads (third intercostal space), and not associated with any relevant symptom. This 
prevalence is significantly lower than that reported in the Japanese study: the 
discrepancy may be explained by the different ethnic background, the Brugada 
syndrome being more frequent in the Asian than the Caucasian population. 
Although no SCD events were observed in our cohort, our findings confirm the need 
for accurate and serial ECG evaluation to identify Brugada-like repolarisation 
abnormalities. Thus, our suggestion is to record lead V1-V2 over the III and II 
intercostal space, to enhance the sensitivity for detection of Brugada like ECG-
changes. Patients presenting with a Brugada-like ECG should be prudently advised 
to prevent and correct hypokalaemia, to promptly treat a fever >38° by antipyretic 
therapy, and to use caution in taking antiarrhythmic drugs known to worsen ECG 
abnormalities and potentially trigger ventricular tachyarrhythmias in BS. 
 
 
 
 
 
 
 93 
CONCLUSIONS 
 
The present studies provide new insights in the risk stratification and treatment of 
patients with cardiomyopathies and channelopathies. 
The first study indicates that besides a history of cardiac arrest or syncope, first-
degree AV block is an independent predictor of malignant arrhythmic events and a 
stroŶger ŵarker of arrhǇthŵiĐ risk thaŶ a spoŶtaŶeous ͞Đoǀed-tǇpe͟ ECG patterŶ.  
The coexistence of ͞Đoǀed-tǇpe͟ right preĐordial “T-segment elevation and 
prolongation of PR interval in those BS patients showing a higher risk of VF supports 
the ĐoŶĐept of a ͞sodiuŵ ioŶ channelopathy͟ ǁhose iŶĐreased ŵǇoĐardial eleĐtriĐal 
instability is the result of a complex interaction between myocardial repolarization 
and depolarization abnormalities. Further experimental and clinical studies are 
needed to better characterize the genetic background, the arrhythmogenic 
mechanisms, the risk stratification accuracy and the therapeutic implications of such 
a dual sodium channel-related phenotype. At the moment, this easily available ECG 
marker should be considered among the clinical and instrumental parameters used 
in designing clinical algorithm for individual risk assessment in BS. 
Our second study reinforces the concept that in young patients with primary 
cardiomyopathies and channelopathies ICD therapy provides life-saving protection 
by effectively terminating life-threatening ventricular arrhythmias and substantially 
reduced the estimated cardiovascular mortality. However, because ICD-related 
adverse events are common, especially lead failure requiring lead extraction, the 
risk/benefit ratio should be carefully assessed when considering ICD implantation in 
young people, especially for primary prevention. Our findings also underline the 
importance of preventing device-related complications with appropriate 
implantation techniques and programming to maintain a favourable benefit–risk 
balance of ICD therapy. 
 94 
Finally, our third study does not confirm the high prevalence of Brugada ECG pattern 
in patients with KD as previously reported in a Japanese study. ECG recording with 
right precordial leads in the upper intercostal spaces is warranted, in order to 
increase the sensitivity for detection of Brugada-like ECG changes in these patients, 
which is a prerequisite for lifestyle changes recommendations. 
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